Background	Background	NNP	B-NP
Sequence	Sequence	NNP	I-NP
homology	homology	NN	I-NP
between	between	IN	0
the	the	DT	0
serotonin	serotonin	JJ	B-NP
type	type	NN	I-NP
3	3	CD	0
receptor	receptor	NN	B-NP
(	(	-LRB-	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
nicotinic	nicotinic	JJ	B-NP
acetylcholine	acetylcholine	JJ	I-NP
receptor	receptor	NN	I-NP
(	(	-LRB-	0
nicotinic	nicotinic	NN	B-NP
acetylcholine	acetylcholine	NN	I-NP
receptor	receptor	NN	I-NP
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
GABA	GABA	NNP	B-NP
A	A	DT	0
receptor	receptor	NN	B-NP
and	and	CC	0
the	the	DT	0
glycine	glycine	JJ	B-NP
receptor	receptor	NN	I-NP
suggests	suggests	VBZ	0
a	a	DT	0
large	large	JJ	0
amount	amount	NN	0
of	of	IN	0
structural	structural	JJ	B-NP
similarity	similarity	NN	I-NP
within	within	IN	0
this	this	DT	0
superfamily	superfamily	NN	0
of	of	IN	0
ligand	ligand	NN	B-NP
gated	gated	FW	0
ion	ion	FW	0
channels	channels	FW	0
[	[	-LRB-	0
1	1	CD	0
2	2	CD	0
3	3	CD	0
]	]	-RRB-	0
.	.	.	0
This	This	DT	0
presumed	presumed	JJ	0
structural	structural	JJ	B-NP
homology	homology	NN	I-NP
can	can	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
guide	guide	VB	0
site	site	NN	0
directed	directed	VBD	0
mutagenesis	mutagenesis	JJ	B-NP
study	study	NN	I-NP
of	of	IN	0
particular	particular	JJ	0
receptor	receptor	NN	B-NP
subtype	subtype	NN	I-NP
.	.	.	0
On	On	IN	0
a	a	DT	0
gross	gross	JJ	0
level	level	NN	0
,	,	,	0
all	all	DT	0
members	members	NNS	0
of	of	IN	0
this	this	DT	0
superfamily	superfamily	JJ	0
assemble	assemble	NN	0
as	as	IN	0
pentameric	pentameric	JJ	B-NP
receptor	receptor	NN	I-NP
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
some	some	DT	0
cases	cases	NNS	0
,	,	,	0
receptor	receptor	NN	B-NP
can	can	MD	0
be	be	VB	0
assembled	assembled	VBN	0
from	from	IN	0
a	a	DT	0
single	single	JJ	0
subunit	subunit	NN	B-NP
(	(	-LRB-	0
5-HT	5-HT	NNP	0
3A	3A	NNP	0
R	R	NNP	0
and	and	CC	0
nicotinic	nicotinic	CD	0
α7	α7	CD	0
receptors	receptors	CD	0
)	)	-RRB-	0
[	[	-LRB-	0
1	1	CD	0
5	5	CD	0
6	6	CD	0
7	7	CD	0
8	8	CD	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
other	other	JJ	0
cases	cases	NNS	0
,	,	,	0
at	at	IN	0
least	least	JJS	0
two	two	CD	0
different	different	JJ	0
subunit	subunit	NN	B-NP
are	are	VBP	0
required	required	VBN	0
[	[	-LRB-	0
2	2	CD	0
4	4	CD	0
9	9	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
ligand	ligand	JJ	B-NP
binding	binding	JJ	I-NP
site	site	NN	I-NP
is	is	VBZ	0
thought	thought	VBN	0
to	to	TO	0
be	be	VB	0
formed	formed	VBN	0
at	at	IN	0
the	the	DT	0
junction	junction	NN	0
between	between	IN	0
two	two	CD	0
subunit	subunit	NN	B-NP
[	[	-LRB-	0
2	2	CD	0
4	4	CD	0
]	]	-RRB-	0
.	.	.	0
Based	Based	VBN	0
on	on	IN	0
data	data	NNS	0
obtained	obtained	VBN	0
from	from	IN	0
affinity	affinity	JJ	B-NP
labeling	labeling	NN	I-NP
and	and	CC	0
site	site	NN	0
directed	directed	VBD	0
mutagenesis	mutagenesis	JJ	B-NP
study	study	NN	I-NP
,	,	,	0
several	several	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
nicotinic	nicotinic	JJ	B-NP
acetylcholine	acetylcholine	JJ	I-NP
receptor	receptor	NN	I-NP
have	have	VBP	0
been	been	VBN	0
implicated	implicated	VBN	0
in	in	IN	0
ligand	ligand	JJ	0
binding	binding	NNS	0
[	[	-LRB-	0
10	10	CD	0
]	]	-RRB-	0
.	.	.	0
Six	Six	CD	0
essential	essential	JJ	B-NP
loop	loop	NN	I-NP
appear	appear	VBP	0
to	to	TO	0
contribute	contribute	VB	0
to	to	TO	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
with	with	IN	0
the	the	DT	0
position	position	NN	0
of	of	IN	0
each	each	DT	0
loop	loop	NN	0
differing	differing	VBG	0
slightly	slightly	RB	0
depending	depending	VBG	0
on	on	RP	0
whether	whether	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
is	is	VBZ	0
heteromeric	heteromeric	VBN	0
or	or	CC	0
homomeric	homomeric	NN	B-NP
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
.	.	.	0
For	For	IN	0
homomeric	homomeric	JJ	B-NP
receptor	receptor	NN	I-NP
such	such	JJ	0
as	as	IN	0
the	the	DT	0
α7	α7	NNP	0
nAChR	nAChR	NNP	0
,	,	,	0
the	the	DT	0
loops	loops	NNS	0
are	are	VBP	0
identified	identified	VBN	0
as	as	IN	0
A	A	NNP	0
,	,	,	0
B	B	NNP	0
,	,	,	0
C	C	NNP	0
,	,	,	0
D	D	NNP	0
,	,	,	0
E	E	NNP	0
and	and	CC	0
F	F	NNP	0
[	[	-LRB-	0
4	4	CD	0
11	11	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
amino	amino	JJ	0
acids	acids	NNS	0
that	that	IN	0
interact	interact	NN	0
with	with	IN	0
ligands	ligands	VBG	0
presumably	presumably	RB	0
extend	extend	VB	0
into	into	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
from	from	IN	0
these	these	DT	0
loops	loops	NNS	0
.	.	.	0
subunit	subunit	NN	B-NP
are	are	VBP	0
composed	composed	VBN	0
of	of	IN	0
2	2	CD	0
faces	faces	NNS	0
(	(	-LRB-	0
+	+	NNP	0
and	and	CC	0
-	-	NNP	0
)	)	-RRB-	0
with	with	IN	0
the	the	DT	0
+	+	JJ	0
face	face	NN	0
of	of	IN	0
one	one	CD	0
subunit	subunit	CD	B-NP
forming	forming	CD	0
one	one	CD	0
side	side	NN	0
of	of	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
and	and	CC	0
the	the	DT	0
-	-	:	0
face	face	NN	0
of	of	IN	0
another	another	DT	0
subunit	subunit	NN	B-NP
forming	forming	VBG	0
the	the	DT	0
complimentary	complimentary	JJ	B-NP
side	side	NN	I-NP
.	.	.	0
Some	Some	DT	0
binding	binding	JJ	0
loops	loops	NNS	0
(	(	-LRB-	0
A	A	NNP	0
,	,	,	0
B	B	NNP	0
and	and	CC	0
C	C	NNP	0
)	)	-RRB-	0
are	are	VBP	0
present	present	JJ	0
on	on	IN	0
the	the	DT	0
-	-	:	0
face	face	NN	0
while	while	IN	0
the	the	DT	0
remaining	remaining	JJ	0
loops	loops	NNS	0
(	(	-LRB-	0
D	D	NNP	0
and	and	CC	0
E	E	NNP	0
)	)	-RRB-	0
are	are	VBP	0
present	present	JJ	0
on	on	IN	0
the	the	DT	0
+	+	NNP	0
face.	face.	NNP	0
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
individual	individual	JJ	B-NP
amino	amino	JJ	I-NP
acid	acid	JJ	I-NP
that	that	WDT	0
form	form	VBP	0
binding	binding	JJ	0
interaction	interaction	NN	B-NP
with	with	IN	0
the	the	DT	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
present	present	JJ	0
on	on	IN	0
a	a	DT	0
ligand	ligand	NN	B-NP
are	are	VBP	0
likely	likely	JJ	0
to	to	TO	0
differ	differ	VB	0
for	for	IN	0
each	each	DT	0
receptor	receptor	NN	B-NP
subtype	subtype	NN	I-NP
,	,	,	0
reflecting	reflecting	VBG	0
the	the	DT	0
specificity	specificity	NN	0
of	of	IN	0
a	a	DT	0
particular	particular	JJ	0
binding	binding	JJ	0
site	site	NN	0
,	,	,	0
however	however	RB	0
,	,	,	0
the	the	DT	0
overall	overall	JJ	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
binding	binding	JJ	0
domain	domain	NN	0
may	may	MD	0
be	be	VB	0
similar	similar	JJ	0
even	even	RB	0
for	for	IN	0
binding	binding	JJ	0
sites	sites	NNS	0
with	with	IN	0
different	different	JJ	0
ligand	ligand	JJ	B-NP
specificity	specificity	NN	I-NP
.	.	.	0
ligand	ligand	JJ	B-NP
specificity	specificity	NN	I-NP
identification	identification	NN	I-NP
requires	requires	VBZ	0
identification	identification	VBN	B-NP
of	of	IN	0
both	both	PDT	0
the	the	DT	0
location	location	NN	0
or	or	CC	0
structure	structure	NN	0
of	of	IN	0
individual	individual	JJ	B-NP
binding	binding	JJ	I-NP
site	site	NN	I-NP
loop	loop	NN	I-NP
and	and	CC	0
the	the	DT	0
amino	amino	JJ	0
acids	acids	JJ	0
present	present	NN	0
in	in	IN	0
a	a	DT	0
particular	particular	JJ	0
receptor	receptor	NN	B-NP
subtype	subtype	NN	I-NP
.	.	.	0
The	The	DT	0
purpose	purpose	NN	0
of	of	IN	0
this	this	DT	0
study	study	NN	0
is	is	VBZ	0
to	to	TO	0
extend	extend	VB	0
the	the	DT	0
information	information	NN	0
available	available	JJ	0
from	from	IN	0
other	other	JJ	0
members	members	NNS	0
of	of	IN	0
this	this	DT	0
receptor	receptor	NN	B-NP
family	family	NN	I-NP
to	to	TO	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R.	R.	NNP	B-NP
Sequence	Sequence	NNP	I-NP
homology	homology	NN	I-NP
and	and	CC	0
a	a	DT	0
presumed	presumed	JJ	0
structural	structural	JJ	B-NP
similarity	similarity	NN	I-NP
to	to	TO	0
other	other	JJ	0
ligand	ligand	NN	B-NP
gated	gated	FW	0
ion	ion	FW	0
channels	channels	FW	0
suggests	suggests	VBZ	0
that	that	IN	0
the	the	DT	0
E	E	NN	B-NP
loop	loop	NN	I-NP
region	region	NN	I-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3A	3A	CD	0
R	R	NN	0
forms	forms	NNS	0
part	part	NN	0
of	of	IN	0
the	the	DT	0
ligand	ligand	JJ	B-NP
binding	binding	JJ	I-NP
domain	domain	NN	I-NP
for	for	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
.	.	.	0
This	This	DT	0
region	region	NN	0
extends	extends	VBZ	0
from	from	IN	0
Y140	Y140	CD	B-NP
to	to	TO	0
K153	K153	CD	B-NP
and	and	CC	0
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
Table	Table	NNP	0
1	1	CD	0
.	.	.	0
The	The	DT	0
homologous	homologous	JJ	B-NP
sequence	sequence	NN	I-NP
of	of	IN	0
other	other	JJ	0
representative	representative	NN	B-NP
member	member	NN	I-NP
of	of	IN	0
this	this	DT	0
family	family	NN	0
are	are	VBP	0
also	also	RB	0
shown	shown	VBN	0
.	.	.	0
In	In	IN	0
the	the	DT	0
center	center	NN	0
of	of	IN	0
this	this	DT	0
region	region	NN	0
is	is	VBZ	0
a	a	DT	0
critical	critical	JJ	B-NP
glycine	glycine	JJ	I-NP
residue	residue	NN	I-NP
that	that	WDT	0
is	is	VBZ	0
thought	thought	VBN	0
to	to	TO	0
play	play	VB	0
a	a	DT	0
role	role	NN	0
in	in	IN	0
establishing	establishing	VBG	0
a	a	DT	0
hairpin	hairpin	JJ	0
loop	loop	NNS	0
[	[	-LRB-	0
12	12	CD	0
]	]	-RRB-	0
.	.	.	0
crystallographic	crystallographic	JJ	B-NP
data	data	NNS	I-NP
recent	recent	JJ	I-NP
x-ray	x-ray	JJ	I-NP
obtained	obtained	VBN	0
from	from	IN	0
an	an	DT	0
ACh	ACh	JJ	B-NP
binding	binding	JJ	I-NP
protein	protein	NN	I-NP
(	(	-LRB-	0
AChBP	AChBP	NNP	B-NP
)	)	-RRB-	0
shows	shows	VBZ	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
in	in	IN	0
this	this	DT	0
region	region	NN	0
resulting	resulting	VBG	0
from	from	IN	0
a	a	DT	0
3	3	CD	0
residue	residue	NNS	0
turn	turn	VBP	0
containing	containing	VBG	0
a	a	DT	0
glycine	glycine	JJ	B-NP
homologous	homologous	NN	I-NP
to	to	TO	0
G147	G147	CD	B-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R.	R.	NNP	0
On	On	IN	0
either	either	DT	0
side	side	NN	0
of	of	IN	0
this	this	DT	0
putative	putative	JJ	B-NP
turn	turn	NN	I-NP
region	region	NN	I-NP
are	are	VBP	0
residues	residues	NNS	0
that	that	WDT	0
have	have	VBP	0
been	been	VBN	0
identified	identified	VBN	0
as	as	IN	0
important	important	JJ	0
to	to	TO	0
receptor	receptor	VB	0
binding	binding	JJ	0
[	[	-LRB-	0
12	12	CD	0
13	13	CD	0
14	14	CD	0
15	15	CD	0
16	16	CD	0
17	17	CD	0
18	18	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
formation	formation	NN	0
of	of	IN	0
this	this	DT	0
loop	loop	JJ	0
structure	structure	NN	0
brings	brings	VBZ	0
amino	amino	JJ	0
acids	acids	NNS	0
on	on	IN	0
either	either	DT	0
side	side	NN	0
of	of	IN	0
glycine	glycine	NN	B-NP
into	into	IN	0
close	close	JJ	0
proximity	proximity	NN	0
and	and	CC	0
may	may	MD	0
form	form	VB	0
a	a	DT	0
binding	binding	JJ	0
pocket	pocket	NN	0
that	that	WDT	0
will	will	MD	0
accommodate	accommodate	VB	0
one	one	CD	0
or	or	CC	0
more	more	RBR	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
In	In	IN	0
order	order	NN	0
to	to	TO	0
identify	identify	VB	0
the	the	DT	0
interaction	interaction	NN	0
of	of	IN	0
amino	amino	JJ	0
acids	acids	NNS	0
in	in	IN	0
this	this	DT	0
binding	binding	JJ	0
loop	loop	NN	0
with	with	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
,	,	,	0
we	we	PRP	0
have	have	VBP	0
constructed	constructed	VBN	0
alanine	alanine	JJ	B-NP
mutation	mutation	NN	I-NP
of	of	IN	0
residues	residues	NNS	0
throughout	throughout	IN	0
this	this	DT	0
region	region	NN	0
and	and	CC	0
evaluated	evaluated	VBD	0
the	the	DT	0
alteration	alteration	NN	0
in	in	IN	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
of	of	IN	0
5	5	CD	0
different	different	JJ	0
classes	classes	NNS	0
of	of	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
(	(	-LRB-	0
Figure	Figure	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
Our	Our	PRP$	0
data	data	NN	0
identifies	identifies	VBZ	0
3	3	CD	0
tyrosine	tyrosine	CD	B-NP
residue	residue	NN	I-NP
that	that	WDT	0
appear	appear	VBP	0
to	to	TO	0
interact	interact	VB	0
selectively	selectively	RB	0
with	with	IN	0
each	each	DT	0
structural	structural	JJ	B-NP
class	class	NN	I-NP
and	and	CC	0
supports	supports	VBZ	0
the	the	DT	0
existence	existence	NN	0
of	of	IN	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
in	in	IN	0
this	this	DT	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
.	.	.	0
Results	Results	NNS	0
All	All	DT	0
mutant	mutant	JJ	B-NP
receptor	receptor	NN	I-NP
were	were	VBD	0
tested	tested	VBN	0
for	for	IN	0
their	their	PRP$	0
ability	ability	NN	B-NP
to	to	TO	0
bind	bind	VB	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	B-NP
antagonist	antagonist	NN	I-NP
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
.	.	.	0
Table	Table	NN	0
2shows	2shows	VBZ	0
the	the	DT	0
K	K	NNP	0
d	d	NN	0
values	values	NNS	0
for	for	IN	0
wildtype	wildtype	JJ	0
mouse	mouse	NN	0
5-HT	5-HT	NNP	0
3AS	3AS	NNP	0
Rs	Rs	NNP	0
and	and	CC	0
the	the	DT	0
13	13	CD	0
alanine	alanine	NNS	B-NP
mutation	mutation	NN	I-NP
we	we	PRP	0
evaluated.	evaluated.	VBP	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
is	is	VBZ	0
a	a	DT	0
potent	potent	JJ	0
antagonist	antagonist	NN	0
of	of	IN	0
the	the	DT	0
wt	wt	JJ	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
(	(	-LRB-	0
K	K	NNP	0
d	d	SYM	0
=	=	SYM	0
0.98	0.98	FW	0
±	±	FW	0
0.12	0.12	FW	0
nM	nM	NN	B-NP
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
value	value	NN	0
agrees	agrees	VBZ	0
with	with	IN	0
published	published	JJ	0
data	data	NNS	0
for	for	IN	0
this	this	DT	0
compound	compound	NN	B-NP
[	[	-LRB-	0
19	19	CD	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
b	b	NN	B-NP
max	max	JJ	I-NP
value	value	NN	I-NP
range	range	VBP	0
from	from	IN	0
the	the	DT	0
5.5	5.5	CD	0
pmoles	pmoles	CD	B-NP
/	/	CD	I-NP
mg	mg	JJ	I-NP
protein	protein	NN	I-NP
observed	observed	VBD	0
for	for	IN	0
E148A	E148A	CD	0
to	to	TO	0
0.30	0.30	CD	0
pmoles	pmoles	CD	B-NP
/	/	CD	I-NP
mg	mg	JJ	I-NP
protein	protein	NN	I-NP
for	for	IN	0
the	the	DT	0
K153A	K153A	JJ	0
mutation	mutation	NN	0
,	,	,	0
indicating	indicating	VBG	0
some	some	DT	0
variability	variability	NN	0
in	in	IN	0
expression	expression	NN	0
of	of	IN	0
the	the	DT	0
different	different	JJ	0
receptor	receptor	NN	B-NP
.	.	.	0
In	In	IN	0
general	general	JJ	0
,	,	,	0
however	however	RB	0
,	,	,	0
receptor	receptor	JJ	B-NP
expression	expression	NN	I-NP
was	was	VBD	0
similar	similar	JJ	0
to	to	TO	0
that	that	WDT	0
reported	reported	VBD	0
by	by	IN	0
other	other	JJ	0
laboratories	laboratories	NNS	0
[	[	-LRB-	0
1	1	CD	0
20	20	CD	0
21	21	CD	0
22	22	CD	0
]	]	-RRB-	0
.	.	.	0
No	No	DT	0
detectable	detectable	JJ	0
binding	binding	NN	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
G147A	G147A	NNP	0
and	and	CC	0
V149A	V149A	CD	0
mutant	mutant	CD	0
receptors	receptors	NNS	0
.	.	.	0
For	For	IN	0
all	all	DT	0
other	other	JJ	0
mutant	mutant	NN	B-NP
,	,	,	0
decreases	decreases	NNS	0
in	in	IN	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
(	(	-LRB-	0
increased	increased	VBN	B-NP
K	K	NN	I-NP
d	d	LS	I-NP
)	)	-RRB-	0
were	were	VBD	0
observed	observed	VBN	0
although	although	IN	0
the	the	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
change	change	NN	0
was	was	VBD	0
less	less	JJR	0
than	than	IN	0
10	10	CD	0
fold	fold	NN	0
in	in	IN	0
all	all	DT	0
cases	cases	NNS	0
.	.	.	0
A	A	DT	0
bar	bar	NN	0
graph	graph	NN	0
showing	showing	VBG	0
the	the	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	B-NP
d	d	JJ	I-NP
value	value	NN	I-NP
resulting	resulting	VBG	0
from	from	IN	0
each	each	DT	0
alanine	alanine	JJ	B-NP
mutation	mutation	NN	I-NP
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
Figure	Figure	NNP	0
2A	2A	NNP	0
.	.	.	0
The	The	DT	0
largest	largest	JJS	0
decreases	decreases	NNS	0
in	in	IN	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
were	were	VBD	0
observed	observed	VBN	0
for	for	IN	0
Y142A	Y142A	NNP	0
(	(	-LRB-	0
4.6	4.6	CD	0
fold	fold	NN	0
,	,	,	0
Figure	Figure	NNP	0
3	3	CD	0
)	)	-RRB-	0
,	,	,	0
E148A	E148A	NNP	0
(	(	-LRB-	0
5.3	5.3	CD	0
fold	fold	CD	0
)	)	-RRB-	0
and	and	CC	0
Q150A	Q150A	NNP	0
-	-	:	0
K153A	K153A	CD	0
(	(	-LRB-	0
6	6	CD	0
-	-	:	0
8	8	CD	0
fold	fold	CD	0
)	)	-RRB-	0
.	.	.	0
Inhibition	Inhibition	JJ	0
binding	binding	JJ	0
assays	assays	NN	0
were	were	VBD	0
also	also	RB	0
conducted	conducted	VBN	0
.	.	.	0
Four	Four	CD	0
test	test	NN	B-NP
compound	compound	JJ	I-NP
with	with	IN	0
structures	structures	JJ	B-NP
representative	representative	NN	I-NP
of	of	IN	0
the	the	DT	0
major	major	JJ	0
classes	classes	NNS	0
of	of	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
were	were	VBD	0
chosen	chosen	VBN	0
:	:	:	0
serotonin	serotonin	CD	B-NP
(	(	-LRB-	0
5-HT	5-HT	NNP	0
,	,	,	0
the	the	DT	0
endogenous	endogenous	JJ	B-NP
agonist	agonist	NN	I-NP
)	)	-RRB-	0
,	,	,	0
m	m	JJ	0
-chlorophenylbiguanide	-chlorophenylbiguanide	NN	0
(	(	-LRB-	0
m	m	UH	0
CPBG	CPBG	UH	B-NP
,	,	,	0
agonist	agonist	CD	B-NP
)	)	-RRB-	0
,	,	,	0
d	d	JJ	0
-tubocurarine	-tubocurarine	NN	0
(	(	-LRB-	0
d	d	LS	0
-tc	-tc	JJ	0
,	,	,	0
antagonist	antagonist	CD	0
)	)	-RRB-	0
and	and	CC	0
lerisetron	lerisetron	NN	B-NP
(	(	-LRB-	0
antagonist	antagonist	LS	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
for	for	IN	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	B-NP
binding	binding	NN	I-NP
by	by	IN	0
all	all	DT	0
four	four	CD	0
compounds	compounds	NNS	0
are	are	VBP	0
shown	shown	VBN	0
in	in	IN	0
Table	Table	NNP	0
3	3	CD	0
.	.	.	0
Little	Little	JJ	B-NP
change	change	NN	I-NP
in	in	IN	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
the	the	DT	0
majority	majority	NN	0
of	of	IN	0
mutations	mutations	NNS	0
.	.	.	0
The	The	DT	0
values	values	NNS	0
highlighted	highlighted	VBD	0
in	in	IN	0
bold	bold	JJ	0
in	in	IN	0
Table	Table	NNP	0
3represent	3represent	CD	0
the	the	DT	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
for	for	IN	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	B-NP
binding	binding	NN	I-NP
on	on	IN	0
mutant	mutant	JJ	B-NP
receptor	receptor	NN	I-NP
that	that	WDT	0
increased	increased	VBD	0
over	over	IN	0
10	10	CD	0
fold	fold	NNS	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
K	K	NNP	0
i	i	VBD	0
obtained	obtained	VBN	0
for	for	IN	0
wildtype	wildtype	JJ	B-NP
receptor	receptor	NN	I-NP
.	.	.	0
The	The	DT	0
bar	bar	NN	0
chart	chart	NN	0
in	in	IN	0
Figure	Figure	NNP	0
2Billustrates	2Billustrates	CD	0
the	the	DT	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	VBZ	0
resulting	resulting	VBG	0
from	from	IN	0
each	each	DT	0
mutation	mutation	NN	0
on	on	IN	0
the	the	DT	0
test	test	NN	B-NP
compound	compound	JJ	I-NP
.	.	.	0
Ratios	Ratios	NNS	0
of	of	IN	0
K	K	NNP	0
i	i	NNS	0
are	are	VBP	0
shown	shown	VBN	0
as	as	IN	0
positive	positive	JJ	0
for	for	IN	0
increases	increases	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
on	on	FW	0
mutant	mutant	NN	B-NP
receptor	receptor	NN	I-NP
versus	versus	FW	0
wildtype	wildtype	NN	B-NP
and	and	CC	0
negative	negative	JJ	0
for	for	IN	0
decreases	decreases	NNS	0
.	.	.	0
A	A	DT	0
positive	positive	JJ	B-NP
change	change	NN	I-NP
thus	thus	RB	0
corresponds	corresponds	VBN	0
to	to	TO	0
a	a	DT	0
decrease	decrease	NN	0
in	in	IN	0
binding	binding	JJ	0
compound	compound	NN	B-NP
affinity	affinity	NN	I-NP
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
mutation	mutation	NN	0
.	.	.	0
large	large	JJ	B-NP
decrease	decrease	NN	I-NP
in	in	IN	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
were	were	VBD	0
observed	observed	VBN	0
for	for	IN	0
select	select	JJ	0
compounds	compounds	NNS	0
only	only	RB	0
on	on	IN	0
the	the	DT	0
Y140A	Y140A	NNP	0
,	,	,	0
Y142A	Y142A	NNP	0
and	and	CC	0
Y152A	Y152A	CD	0
mutations	mutations	NNS	0
.	.	.	0
A	A	DT	0
more	more	RBR	0
detailed	detailed	JJ	0
analysis	analysis	NN	0
of	of	IN	0
the	the	DT	0
competition	competition	NN	0
binding	binding	JJ	0
data	data	NNS	0
obtained	obtained	VBN	0
for	for	IN	0
the	the	DT	0
Y140A	Y140A	NNP	0
,	,	,	0
Y142A	Y142A	NNP	0
and	and	CC	0
Y152A	Y152A	CD	0
mutations	mutations	NN	0
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
Figure	Figure	NNP	0
4	4	CD	0
.	.	.	0
For	For	IN	0
5-HT	5-HT	NNP	0
,	,	,	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
produced	produced	VBD	0
a	a	DT	0
110	110	CD	0
fold	fold	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
and	and	CC	0
Y152A	Y152A	NNP	0
produced	produced	VBD	0
a	a	DT	0
24	24	CD	0
fold	fold	JJ	0
increase	increase	NN	0
.	.	.	0
No	No	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
the	the	DT	0
Y140A	Y140A	JJ	0
mutation	mutation	NN	0
(	(	-LRB-	0
Figure	Figure	NNP	0
4A	4A	NNP	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
agonist	agonist	NNS	0
m	m	VBD	0
CPBG	CPBG	NNP	0
showed	showed	VBD	0
a	a	DT	0
similar	similar	JJ	0
profile	profile	NN	0
for	for	IN	0
the	the	DT	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
values	values	VBZ	0
resulting	resulting	VBG	0
from	from	IN	0
mutations	mutations	NNS	0
of	of	IN	0
the	the	DT	0
three	three	CD	0
tyrosines	tyrosines	NNS	0
(	(	-LRB-	0
Figure	Figure	NNP	0
4B	4B	NNP	0
)	)	-RRB-	0
.	.	.	0
As	As	RB	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
5-HT	5-HT	NNP	0
,	,	,	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
produced	produced	VBD	0
a	a	DT	0
large	large	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
(	(	-LRB-	0
160	160	CD	0
fold	fold	CD	0
)	)	-RRB-	0
while	while	IN	0
the	the	DT	0
Y14	Y14	NNP	0
0A	0A	NNP	0
and	and	CC	0
Y152A	Y152A	CD	0
mutations	mutations	NNS	0
produced	produced	VBD	0
only	only	RB	0
7	7	CD	0
and	and	CC	0
24	24	CD	0
fold	fold	CD	0
changes	changes	NNS	0
respectively	respectively	RB	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
for	for	IN	0
d	d	JJ	0
-tc	-tc	JJ	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	0
binding	binding	NN	0
was	was	VBD	0
altered	altered	VBN	0
only	only	RB	0
slightly	slightly	RB	0
by	by	IN	0
the	the	DT	0
Y142A	Y142A	NNP	0
or	or	CC	0
Y152A	Y152A	CD	0
mutations	mutations	NNS	0
(	(	-LRB-	0
6.5	6.5	CD	0
fold	fold	NNS	0
and	and	CC	0
10	10	CD	0
fold	fold	CD	0
changes	changes	NNS	0
respectively	respectively	RB	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
Y140A	Y140A	JJ	0
mutation	mutation	NN	0
,	,	,	0
however	however	RB	0
,	,	,	0
produced	produced	VBD	0
a	a	DT	0
50	50	CD	0
fold	fold	JJ	0
increase	increase	NN	0
in	in	IN	0
the	the	DT	0
K	K	NNP	0
i	i	VBD	0
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptors	receptors	NNS	0
(	(	-LRB-	0
Figure	Figure	NNP	0
4C	4C	NNP	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
for	for	IN	0
lerisetron	lerisetron	JJ	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	0
binding	binding	NN	0
was	was	VBD	0
increased	increased	VBN	0
160	160	CD	0
fold	fold	NN	0
by	by	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
and	and	CC	0
190	190	CD	0
fold	fold	NN	0
by	by	IN	0
the	the	DT	0
Y152A	Y152A	JJ	0
mutation	mutation	NN	0
.	.	.	0
Only	Only	RB	0
a	a	DT	0
4.6	4.6	CD	0
fold	fold	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	VBD	0
resulted	resulted	VBN	0
from	from	IN	0
the	the	DT	0
Y140A	Y140A	JJ	0
mutation	mutation	NN	0
.	.	.	0
Lerisetron	Lerisetron	NNP	0
was	was	VBD	0
the	the	DT	0
only	only	JJ	0
compound	compound	NN	0
for	for	IN	0
which	which	WDT	0
a	a	DT	0
large	large	JJ	0
increase	increase	NN	0
in	in	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
was	was	VBD	0
observed	observed	VBN	0
on	on	IN	0
the	the	DT	0
Y152A	Y152A	JJ	0
mutation	mutation	NN	0
(	(	-LRB-	0
Figure	Figure	NNP	0
4D	4D	NNP	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
mutation	mutation	NN	0
produced	produced	VBD	0
smaller	smaller	JJR	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
5-HT	5-HT	NNP	0
and	and	CC	0
m	m	JJ	0
CPBG	CPBG	NNP	0
(	(	-LRB-	0
24	24	CD	0
fold	fold	NN	0
for	for	IN	0
both	both	DT	0
)	)	-RRB-	0
and	and	CC	0
only	only	RB	0
a	a	DT	0
10	10	CD	0
fold	fold	JJ	0
change	change	NN	0
for	for	IN	0
d	d	JJ	0
-tc	-tc	NN	0
.	.	.	0
In	In	IN	0
whole	whole	JJ	0
cell	cell	NN	0
patch	patch	NN	0
clamp	clamp	NN	0
studies	studies	NNS	0
,	,	,	0
5-HT	5-HT	CD	0
perfusion	perfusion	NN	0
of	of	IN	0
cells	cells	NNS	0
transfected	transfected	VBN	0
with	with	IN	0
Y140A	Y140A	NNP	0
and	and	CC	0
Y142A	Y142A	NNP	0
cDNA	cDNA	NNP	0
produced	produced	VBD	0
no	no	DT	0
responses	responses	NNS	0
at	at	IN	0
5-HT	5-HT	CD	0
concentrations	concentrations	NNS	0
of	of	IN	0
up	up	RB	0
to	to	TO	0
1	1	CD	0
mM	mM	NN	0
although	although	IN	0
specific	specific	JJ	0
binding	binding	NN	0
to	to	TO	0
these	these	DT	0
receptor	receptor	NN	B-NP
was	was	VBD	0
identified	identified	VBN	0
in	in	IN	0
receptor	receptor	JJ	B-NP
binding	binding	JJ	I-NP
study	study	NN	I-NP
.	.	.	0
Unlike	Unlike	IN	0
Y140A	Y140A	NNP	0
and	and	CC	0
Y142A	Y142A	NNP	0
,	,	,	0
Y152A	Y152A	CD	0
receptors	receptors	NNS	0
responded	responded	VBD	0
to	to	TO	0
application	application	NN	0
of	of	IN	0
5-HT	5-HT	CD	0
.	.	.	0
Due	Due	JJ	0
to	to	TO	0
the	the	DT	0
low	low	JJ	0
potency	potency	NN	0
of	of	IN	0
5-HT	5-HT	CD	0
on	on	IN	0
these	these	DT	0
receptor	receptor	NN	B-NP
,	,	,	0
only	only	RB	0
a	a	DT	0
portion	portion	NN	0
of	of	IN	0
the	the	DT	0
concentration	concentration	NN	B-NP
response	response	NN	I-NP
curve	curve	NN	I-NP
could	could	MD	0
be	be	VB	0
determined	determined	VBN	0
(	(	-LRB-	0
up	up	RB	0
to	to	TO	0
1	1	CD	0
mM	mM	NN	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
EC	EC	NNP	B-NP
50	50	CD	0
value	value	NN	0
was	was	VBD	0
estimated	estimated	VBN	0
as	as	IN	0
greater	greater	JJR	0
than	than	IN	0
370	370	CD	0
μM	μM	NN	B-NP
(	(	-LRB-	0
Figure	Figure	NNP	0
5	5	CD	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
value	value	NN	0
shows	shows	VBZ	0
a	a	DT	0
greater	greater	JJR	0
than	than	IN	0
140	140	CD	0
fold	fold	JJ	0
increase	increase	NN	0
in	in	IN	0
EC	EC	NNP	B-NP
50	50	CD	0
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptor	receptor	NN	B-NP
;	;	:	0
a	a	DT	0
larger	larger	JJR	0
change	change	NN	0
than	than	IN	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
the	the	DT	0
K	K	NNP	0
i	i	FW	0
(	(	-LRB-	0
24	24	CD	0
fold	fold	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
most	most	RBS	0
dramatic	dramatic	JJ	0
change	change	NN	0
observed	observed	VBD	0
for	for	IN	0
whole	whole	JJ	0
cell	cell	NN	0
currents	currents	NNS	0
was	was	VBD	0
an	an	DT	0
alteration	alteration	NN	0
in	in	IN	0
the	the	DT	0
kinetics	kinetics	NN	0
of	of	IN	0
the	the	DT	0
response	response	NN	B-NP
elicited	elicited	NN	I-NP
by	by	IN	0
application	application	NN	0
of	of	IN	0
5-HT	5-HT	CD	0
.	.	.	0
Y152A	Y152A	NNP	0
mutant	mutant	JJ	0
receptors	receptors	NNS	0
displayed	displayed	VBD	0
much	much	RB	0
slower	slower	JJR	0
rise	rise	NN	B-NP
time	time	NN	I-NP
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptors	receptors	VBN	0
at	at	IN	0
all	all	DT	0
concentration	concentration	NN	B-NP
tested	tested	VBD	0
.	.	.	0
Peak	Peak	JJ	0
wt	wt	JJ	B-NP
response	response	NN	I-NP
were	were	VBD	0
typically	typically	RB	0
obtained	obtained	VBN	0
in	in	IN	0
less	less	JJR	0
than	than	IN	0
80	80	CD	0
m	m	NN	B-NP
while	while	IN	0
Y152A	Y152A	CD	0
responses	responses	NNS	0
required	required	VBN	0
several	several	JJ	0
seconds	seconds	NNS	0
to	to	TO	0
plateau	plateau	NN	0
.	.	.	0
Desensitization	Desensitization	JJ	B-NP
kinetics	kinetics	NN	I-NP
were	were	VBD	0
also	also	RB	0
altered	altered	VBN	0
.	.	.	0
While	While	IN	0
wt	wt	JJ	B-NP
receptor	receptor	NN	I-NP
desensitized	desensitized	VBP	0
rapidly	rapidly	RB	0
,	,	,	0
mutant	mutant	JJ	B-NP
receptor	receptor	NN	I-NP
showed	showed	VBD	0
no	no	DT	0
desensitization	desensitization	NN	B-NP
during	during	IN	0
the	the	DT	0
8	8	CD	0
s	s	CD	B-NP
perfusion	perfusion	JJ	I-NP
time	time	NN	I-NP
.	.	.	0
Discussion	Discussion	NN	0
The	The	DT	0
putative	putative	JJ	0
E-loop	E-loop	JJ	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
LGIC	LGIC	NNP	0
family	family	NN	0
of	of	IN	0
receptors	receptors	NN	0
is	is	VBZ	0
homologous	homologous	VBN	0
to	to	TO	0
residues	residues	CD	0
Y140	Y140	CD	0
through	through	IN	0
K153	K153	CD	0
in	in	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
[	[	-LRB-	0
4	4	CD	0
12	12	CD	0
13	13	CD	0
14	14	CD	0
15	15	CD	0
16	16	CD	0
17	17	CD	0
18	18	CD	0
]	]	-RRB-	0
.	.	.	0
structure-function	structure-function	NN	B-NP
study	study	NN	I-NP
of	of	IN	0
this	this	DT	0
region	region	NN	0
have	have	VBP	0
been	been	VBN	0
conducted	conducted	VBN	0
in	in	IN	0
several	several	JJ	0
other	other	JJ	0
members	members	NNS	0
of	of	IN	0
this	this	DT	0
family	family	NN	0
of	of	IN	0
including	including	VBG	B-NP
gaba	gaba	NNP	I-NP
receptor	receptor	NN	I-NP
A	A	NNP	0
and	and	CC	0
nachr	nachr	NN	B-NP
subtype	subtype	NN	I-NP
.	.	.	0
In	In	IN	0
each	each	DT	0
case	case	NN	0
,	,	,	0
residues	residues	NNS	0
have	have	VBP	0
been	been	VBN	0
identified	identified	VBN	0
that	that	IN	0
alter	alter	NN	0
either	either	CC	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
selective	selective	JJ	B-NP
ligand	ligand	NN	I-NP
or	or	CC	0
receptor	receptor	JJ	B-NP
function	function	NN	I-NP
[	[	-LRB-	0
4	4	CD	0
11	11	CD	0
12	12	CD	0
13	13	CD	0
14	14	CD	0
15	15	CD	0
16	16	CD	0
17	17	CD	0
18	18	CD	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
order	order	NN	0
to	to	TO	0
determine	determine	VB	0
if	if	IN	0
this	this	DT	0
loop	loop	NN	0
also	also	RB	0
contains	contains	VBZ	0
residues	residues	JJ	0
critical	critical	JJ	0
to	to	TO	0
the	the	DT	0
structure	structure	NN	0
or	or	CC	0
function	function	NN	0
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
,	,	,	0
we	we	PRP	0
have	have	VBP	0
constructed	constructed	VBN	0
alanine	alanine	JJ	B-NP
mutation	mutation	NN	I-NP
of	of	IN	0
amino	amino	JJ	0
acids	acids	NNS	0
throughout	throughout	IN	0
the	the	DT	0
homologous	homologous	JJ	B-NP
region	region	NN	I-NP
of	of	IN	0
the	the	DT	0
mouse	mouse	NN	0
5-HT	5-HT	CD	0
3AS	3AS	CD	0
R	R	NN	0
and	and	CC	0
investigated	investigated	VBD	0
the	the	DT	0
affects	affects	NN	0
on	on	IN	0
binding	binding	VBG	0
of	of	IN	0
5	5	CD	0
different	different	JJ	0
structural	structural	JJ	B-NP
class	class	NN	I-NP
of	of	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
.	.	.	0
We	We	PRP	0
have	have	VBP	0
identified	identified	VBN	0
three	three	CD	0
tyrosine	tyrosine	CD	B-NP
residue	residue	NN	I-NP
that	that	WDT	0
appear	appear	VBP	0
to	to	TO	0
play	play	VB	0
a	a	DT	0
role	role	NN	0
in	in	IN	0
binding	binding	VBG	0
of	of	IN	0
selective	selective	JJ	B-NP
ligand	ligand	NN	I-NP
to	to	TO	0
this	this	DT	0
receptor	receptor	NN	B-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
our	our	PRP$	0
data	data	NNS	0
support	support	VBP	0
the	the	DT	0
existence	existence	NN	0
of	of	IN	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
in	in	IN	0
this	this	DT	0
region	region	NN	0
as	as	RB	0
has	has	VBZ	0
been	been	VBN	0
hypothesized	hypothesized	VBN	0
for	for	IN	0
the	the	DT	0
nAChR	nAChR	JJ	0
and	and	CC	0
identified	identified	VBN	0
in	in	IN	0
a	a	DT	0
homologous	homologous	JJ	B-NP
AChBP	AChBP	NN	I-NP
[	[	-LRB-	0
12	12	CD	0
23	23	CD	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
representative	representative	JJ	B-NP
member	member	NN	I-NP
of	of	IN	0
5	5	CD	0
major	major	JJ	0
structural	structural	JJ	B-NP
class	class	NN	I-NP
of	of	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
were	were	VBD	0
tested	tested	VBN	0
on	on	IN	0
all	all	DT	0
mutant	mutant	NN	B-NP
(	(	-LRB-	0
Figure	Figure	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
ligand	ligand	NN	B-NP
include	include	VBP	0
the	the	DT	0
antagonists	antagonists	NNS	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
,	,	,	0
d	d	JJ	0
-tc	-tc	JJ	0
and	and	CC	0
lerisetron	lerisetron	NN	B-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
agonists	agonists	JJ	0
5-HT	5-HT	NN	0
and	and	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
.	.	.	0
Most	Most	JJS	0
of	of	IN	0
the	the	DT	0
mutations	mutations	NN	0
tested	tested	VBD	0
produced	produced	VBN	0
only	only	RB	0
minor	minor	JJ	0
changes	changes	NNS	0
in	in	IN	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
for	for	IN	0
these	these	DT	0
ligand	ligand	NN	B-NP
.	.	.	0
large	large	JJ	B-NP
change	change	NN	I-NP
in	in	IN	0
binding	binding	NNS	0
are	are	VBP	0
only	only	RB	0
apparent	apparent	JJ	0
on	on	IN	0
Y140A	Y140A	NNP	0
,	,	,	0
Y142A	Y142A	NNP	0
and	and	CC	0
Y152A	Y152A	CD	0
receptors	receptors	NNS	0
for	for	IN	0
select	select	JJ	0
ligand	ligand	NN	B-NP
.	.	.	0
The	The	DT	0
individual	individual	JJ	B-NP
mutation	mutation	NN	I-NP
resulting	resulting	VBG	I-NP
effect	effect	NN	I-NP
are	are	VBP	0
specific	specific	JJ	0
to	to	TO	0
particular	particular	JJ	0
ligand	ligand	NN	B-NP
structural	structural	JJ	I-NP
class	class	NN	I-NP
.	.	.	0
The	The	DT	0
Y140A	Y140A	JJ	0
mutation	mutation	NN	0
altered	altered	VBD	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
d	d	JJ	0
-tc	-tc	JJ	0
inhibition	inhibition	NN	0
,	,	,	0
but	but	CC	0
did	did	VBD	0
not	not	RB	0
alter	alter	VB	0
the	the	DT	0
K	K	NNP	0
i	i	VBD	0
obtained	obtained	VBN	0
for	for	IN	0
any	any	DT	0
other	other	JJ	0
compound	compound	NN	B-NP
tested	tested	VBD	0
,	,	,	0
while	while	IN	0
Y142A	Y142A	NNP	0
altered	altered	VBD	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
,	,	,	0
5-HT	5-HT	NNP	0
and	and	CC	0
lerisetron	lerisetron	NN	B-NP
but	but	CC	0
had	had	VBD	0
little	little	RB	0
if	if	IN	0
any	any	DT	0
effect	effect	NN	0
on	on	IN	0
inhibition	inhibition	NN	0
by	by	IN	0
d	d	JJ	0
-tc	-tc	NN	0
.	.	.	0
These	These	DT	0
data	data	NNS	0
indicate	indicate	VBP	0
the	the	DT	0
highly	highly	RB	0
specific	specific	JJ	0
nature	nature	NN	0
of	of	IN	0
the	the	DT	0
effects	effects	NNS	0
introduced	introduced	VBN	0
by	by	IN	0
the	the	DT	0
alanine	alanine	JJ	B-NP
mutation	mutation	NN	I-NP
and	and	CC	0
appear	appear	VB	0
to	to	TO	0
reflect	reflect	VB	0
specific	specific	JJ	0
changes	changes	NNS	0
in	in	IN	0
ligand	ligand	NN	B-NP
/	/	NN	I-NP
receptor	receptor	NN	I-NP
interaction	interaction	NN	I-NP
.	.	.	0
Binding	Binding	VBG	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
is	is	VBZ	0
altered	altered	VBN	0
only	only	RB	0
slightly	slightly	RB	0
by	by	IN	0
the	the	DT	0
alanine	alanine	JJ	B-NP
mutation	mutation	NN	I-NP
introduced	introduced	VBN	0
in	in	IN	0
this	this	DT	0
study	study	NN	0
(	(	-LRB-	0
<	<	SYM	0
10	10	CD	0
fold	fold	CD	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
result	result	NN	0
indicates	indicates	VBZ	0
the	the	DT	0
lack	lack	NN	0
of	of	IN	0
involvement	involvement	NN	0
of	of	IN	0
amino	amino	JJ	0
acids	acids	NNS	0
in	in	IN	0
this	this	DT	0
binding	binding	JJ	0
loop	loop	NN	0
in	in	IN	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
apparent	apparent	JJ	0
,	,	,	0
however	however	RB	0
,	,	,	0
that	that	WDT	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
does	does	VBZ	0
occupy	occupy	VBG	0
the	the	DT	0
same	same	JJ	0
binding	binding	JJ	0
cleft	cleft	NN	0
as	as	IN	0
other	other	JJ	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
ligands	ligands	VBZ	0
as	as	RB	0
evidenced	evidenced	VBN	0
by	by	IN	0
the	the	DT	0
ability	ability	NN	B-NP
of	of	IN	0
5-HT	5-HT	NNP	0
,	,	,	0
m	m	VBG	0
CPBG	CPBG	NNP	B-NP
,	,	,	0
d	d	JJ	0
-tc	-tc	JJ	0
and	and	CC	0
lerisetron	lerisetron	JJ	0
to	to	TO	0
displace	displace	VB	0
it	it	PRP	0
from	from	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
.	.	.	0
The	The	DT	0
lack	lack	NN	0
of	of	IN	0
any	any	DT	0
large	large	JJ	0
change	change	NN	0
in	in	IN	0
binding	binding	VBG	0
of	of	IN	0
granisetron	granisetron	NN	B-NP
supports	supports	VBZ	0
our	our	PRP$	0
contention	contention	NN	0
that	that	IN	0
there	there	EX	0
is	is	VBZ	0
little	little	RB	0
global	global	JJ	0
structural	structural	JJ	B-NP
perturbation	perturbation	NN	I-NP
of	of	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
resulting	resulting	VBG	0
from	from	IN	0
the	the	DT	0
introduction	introduction	NN	B-NP
of	of	IN	0
each	each	DT	0
individual	individual	JJ	B-NP
alanine	alanine	JJ	I-NP
mutation	mutation	NN	I-NP
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	B-NP
binding	binding	NN	I-NP
by	by	IN	0
5-HT	5-HT	NNP	0
was	was	VBD	0
increased	increased	VBN	0
110	110	CD	0
fold	fold	NN	0
by	by	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
.	.	.	0
A	A	DT	0
similar	similar	JJ	0
increase	increase	NN	0
was	was	VBD	0
also	also	RB	0
observed	observed	VBN	0
for	for	IN	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
(	(	-LRB-	0
160	160	CD	0
fold	fold	CD	0
)	)	-RRB-	0
.	.	.	0
In	In	IN	0
contrast	contrast	NN	0
,	,	,	0
the	the	DT	0
Y140A	Y140A	NNP	0
and	and	CC	0
Y152A	Y152A	CD	0
mutations	mutations	NNS	0
produced	produced	VBD	0
relatively	relatively	RB	0
small	small	JJ	0
changes	changes	NNS	0
in	in	IN	0
the	the	DT	0
K	K	NNP	0
i	i	FW	0
.	.	.	0
Since	Since	IN	0
both	both	DT	0
compounds	compounds	NNS	0
are	are	VBP	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
agonist	agonist	NN	I-NP
,	,	,	0
they	they	PRP	0
are	are	VBP	0
likely	likely	JJ	0
to	to	TO	0
share	share	VB	0
the	the	DT	0
same	same	JJ	0
binding	binding	JJ	0
interaction	interaction	NN	B-NP
.	.	.	0
One	One	CD	0
of	of	IN	0
these	these	DT	0
interaction	interaction	NN	B-NP
appears	appears	VBZ	0
to	to	TO	0
be	be	VB	0
with	with	IN	0
Y142	Y142	CD	B-NP
.	.	.	0
Other	Other	JJ	0
studies	studies	NNS	0
have	have	VBP	0
also	also	RB	0
identified	identified	VBN	0
binding	binding	JJ	0
site	site	NN	0
interactions	interactions	NNS	0
for	for	IN	0
agonist	agonist	NN	B-NP
.	.	.	0
R91	R91	NNP	B-NP
,	,	,	0
E106	E106	NNP	B-NP
,	,	,	0
F107	F107	NNP	B-NP
,	,	,	0
W183	W183	NNP	B-NP
and	and	CC	0
several	several	JJ	0
residues	residues	JJ	0
adjacent	adjacent	JJ	0
to	to	TO	0
the	the	DT	0
M1	M1	JJ	B-NP
region	region	NN	I-NP
have	have	VBP	0
all	all	RB	0
been	been	VBN	0
demonstrated	demonstrated	VBN	0
to	to	TO	0
alter	alter	VB	0
the	the	DT	0
action	action	NN	0
of	of	IN	0
5-HT	5-HT	NNP	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
[	[	-LRB-	0
20	20	CD	0
21	21	CD	0
25	25	CD	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
Within	Within	IN	0
the	the	DT	0
crystal	crystal	NN	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
AChBP	AChBP	JJ	0
,	,	,	0
homologous	homologous	JJ	B-NP
residue	residue	NN	I-NP
are	are	VBP	0
located	located	VBN	0
in	in	IN	0
the	the	DT	0
apparent	apparent	JJ	0
binding	binding	JJ	0
site	site	NN	0
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
effects	effects	NNS	0
of	of	IN	0
agonist	agonist	NN	B-NP
on	on	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
are	are	VBP	0
mediated	mediated	VBN	0
by	by	IN	0
their	their	PRP$	0
interaction	interaction	NN	0
with	with	IN	0
these	these	DT	0
binding	binding	JJ	0
site	site	NN	0
residues	residues	NNS	0
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
stable	stable	JJ	0
receptor	receptor	NN	B-NP
conformation	conformation	NN	I-NP
,	,	,	0
including	including	VBG	0
the	the	DT	0
channel	channel	NN	0
open	open	JJ	0
state	state	NN	0
.	.	.	0
Identification	Identification	NN	B-NP
of	of	IN	0
interacting	interacting	JJ	0
amino	amino	JJ	0
acids	acids	NNS	0
and	and	CC	0
their	their	PRP$	0
location	location	NN	0
in	in	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
tertiary	tertiary	JJ	I-NP
structure	structure	NN	I-NP
may	may	MD	0
provide	provide	VB	0
clues	clues	NNS	0
to	to	TO	0
the	the	DT	0
mechanism	mechanism	NN	0
of	of	IN	0
channel	channel	NN	0
opening	opening	NN	0
.	.	.	0
For	For	IN	0
example	example	NN	0
,	,	,	0
amino	amino	JJ	0
acids	acids	NNS	0
homologous	homologous	VBP	0
to	to	TO	0
Y142	Y142	CD	B-NP
and	and	CC	0
W183	W183	NNP	B-NP
(	(	-LRB-	0
R104	R104	NNP	B-NP
and	and	CC	0
W143	W143	CD	B-NP
respectively	respectively	CD	0
)	)	-RRB-	0
are	are	VBP	0
in	in	IN	0
close	close	JJ	0
proximity	proximity	NN	0
in	in	IN	0
the	the	DT	0
AChBP	AChBP	JJ	0
,	,	,	0
although	although	IN	0
on	on	IN	0
receptor	receptor	NN	B-NP
subunit	subunit	NN	I-NP
complementary	complementary	JJ	I-NP
face	face	NN	I-NP
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
Spier	Spier	NNP	0
et.	et.	NNP	0
al	al	NN	0
.	.	.	0
have	have	VBP	0
suggested	suggested	VBN	0
that	that	IN	0
W183	W183	NNP	B-NP
may	may	MD	0
be	be	VB	0
involved	involved	VBN	0
in	in	IN	0
a	a	DT	0
cation-π	cation-π	JJ	B-NP
interaction	interaction	NN	I-NP
with	with	IN	0
the	the	DT	0
amino	amino	JJ	0
group	group	NN	0
of	of	IN	0
5-HT	5-HT	NNP	0
and	and	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
[	[	-LRB-	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
If	If	IN	0
W183	W183	NNP	B-NP
and	and	CC	0
Y142	Y142	NNP	B-NP
are	are	VBP	0
located	located	VBN	0
near	near	IN	0
each	each	DT	0
other	other	JJ	0
but	but	CC	0
on	on	IN	0
opposite	opposite	NN	0
faces	faces	VBZ	0
of	of	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
in	in	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
,	,	,	0
then	then	RB	0
they	they	PRP	0
could	could	MD	0
potentially	potentially	RB	0
act	act	VB	0
in	in	IN	0
concert	concert	NN	0
to	to	TO	0
help	help	VB	0
stabilize	stabilize	VB	0
a	a	DT	0
receptor	receptor	NN	B-NP
conformation	conformation	NN	I-NP
leading	leading	VBG	0
to	to	TO	0
channel	channel	VB	0
opening.	opening.	CD	0
d	d	SYM	0
-Tubocurarine	-Tubocurarine	JJ	0
inhibition	inhibition	NN	0
was	was	VBD	0
uniquely	uniquely	RB	0
altered	altered	VBN	0
by	by	IN	0
the	the	DT	0
Y140A	Y140A	JJ	0
mutation	mutation	NN	0
.	.	.	0
An	An	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
of	of	IN	0
50	50	CD	0
fold	fold	NNS	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
d	d	JJ	0
-tc	-tc	NN	0
on	on	IN	0
this	this	DT	0
mutant	mutant	NN	B-NP
.	.	.	0
Little	Little	RB	0
if	if	IN	0
any	any	DT	0
change	change	NN	0
resulted	resulted	VBD	0
for	for	IN	0
any	any	DT	0
other	other	JJ	0
mutation	mutation	NN	0
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
while	while	IN	0
d	d	JJ	0
-tc	-tc	NN	0
may	may	MD	0
form	form	VB	0
an	an	DT	0
interaction	interaction	NN	0
with	with	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
at	at	IN	0
this	this	DT	0
binding	binding	JJ	0
loop	loop	NN	0
,	,	,	0
it	it	PRP	0
appears	appears	VBZ	0
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
Y140	Y140	NNP	B-NP
rather	rather	RB	0
than	than	IN	0
Y142	Y142	NNP	B-NP
or	or	CC	0
Y152	Y152	NNP	B-NP
.	.	.	0
This	This	DT	0
difference	difference	NN	0
in	in	IN	0
binding	binding	JJ	0
site	site	NN	0
interactions	interactions	NNS	0
of	of	IN	0
the	the	DT	0
antagonist	antagonist	JJ	0
d	d	JJ	0
-tc	-tc	JJ	0
and	and	CC	0
the	the	DT	0
agonists	agonists	JJ	0
5-HT	5-HT	NN	0
and	and	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
could	could	MD	0
be	be	VB	0
the	the	DT	0
result	result	NN	0
of	of	IN	0
a	a	DT	0
slightly	slightly	RB	0
different	different	JJ	0
positioning	positioning	NN	0
of	of	IN	0
d	d	JJ	0
-tc	-tc	NN	0
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
.	.	.	0
The	The	DT	0
antagonists	antagonists	JJ	0
d	d	JJ	0
-tc	-tc	JJ	0
and	and	CC	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
also	also	RB	0
interact	interact	VBN	0
differently	differently	RB	0
with	with	IN	0
this	this	DT	0
region	region	NN	0
since	since	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	B-NP
binding	binding	NN	I-NP
was	was	VBD	0
not	not	RB	0
altered	altered	VBN	0
by	by	IN	0
mutations	mutations	NNS	0
at	at	IN	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
amino	amino	JJ	0
acids	acids	NNS	0
tested	tested	VBD	0
.	.	.	0
While	While	IN	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
d	d	JJ	0
-tc	-tc	NN	0
appears	appears	VBZ	0
to	to	TO	0
involve	involve	VB	0
some	some	DT	0
interaction	interaction	NN	0
with	with	IN	0
this	this	DT	0
binding	binding	JJ	0
loop	loop	NN	0
,	,	,	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
does	does	VBZ	0
not	not	RB	0
.	.	.	0
previous	previous	JJ	B-NP
study	study	NN	I-NP
have	have	VBP	0
indicated	indicated	VBN	0
a	a	DT	0
point	point	NN	0
of	of	IN	0
overlap	overlap	NN	0
between	between	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
and	and	CC	0
d	d	JJ	0
-tc	-tc	NN	0
at	at	IN	0
W89	W89	CD	B-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	NNP	0
3AS	3AS	NNP	0
R.	R.	NNP	0
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
These	These	DT	0
studies	studies	NNS	0
indicate	indicate	VBP	0
that	that	IN	0
the	the	DT	0
binding	binding	JJ	0
regions	regions	NNS	0
for	for	IN	0
these	these	DT	0
antagonists	antagonists	NNS	0
are	are	VBP	0
partially	partially	RB	0
overlapping	overlapping	VBG	0
at	at	IN	0
W89	W89	NNP	B-NP
but	but	CC	0
not	not	RB	0
at	at	IN	0
Y140	Y140	CD	B-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
to	to	TO	0
Y140	Y140	CD	B-NP
and	and	CC	0
W89	W89	NNP	B-NP
,	,	,	0
d	d	JJ	0
-tc	-tc	NN	0
has	has	VBZ	0
also	also	RB	0
been	been	VBN	0
observed	observed	VBN	0
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
D206	D206	NNP	B-NP
and	and	CC	0
several	several	JJ	0
other	other	JJ	0
residues	residues	NNS	0
in	in	IN	0
loop	loop	JJ	0
C	C	NNP	0
[	[	-LRB-	0
27	27	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
d	d	JJ	0
-tc	-tc	JJ	0
binding	binding	JJ	0
site	site	NN	0
appears	appears	VBZ	0
to	to	TO	0
involve	involve	VB	0
interaction	interaction	VBN	0
with	with	IN	0
at	at	IN	0
least	least	JJS	0
three	three	CD	0
different	different	JJ	0
binding	binding	JJ	0
loops	loops	NNS	0
(	(	-LRB-	0
A	A	NNP	0
,	,	,	0
E	E	NNP	0
and	and	CC	0
C	C	NNP	0
)	)	-RRB-	0
although	although	IN	0
additional	additional	JJ	0
interacting	interacting	JJ	0
amino	amino	JJ	0
acids	acids	NNS	0
may	may	MD	0
be	be	VB	0
found	found	VBN	0
.	.	.	0
Data	Data	NNS	0
obtained	obtained	VBN	0
for	for	IN	0
d	d	JJ	0
-tc	-tc	NN	0
is	is	VBZ	0
particularly	particularly	RB	0
valuable	valuable	JJ	0
due	due	JJ	0
to	to	TO	0
the	the	DT	0
rigid	rigid	JJ	0
nature	nature	NN	0
of	of	IN	0
this	this	DT	0
molecule	molecule	NN	B-NP
.	.	.	0
Determination	Determination	NN	B-NP
of	of	IN	0
interacting	interacting	JJ	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
and	and	CC	0
their	their	PRP$	0
relationship	relationship	NN	B-NP
to	to	TO	0
individual	individual	JJ	B-NP
amino	amino	JJ	I-NP
acid	acid	JJ	I-NP
could	could	MD	0
enable	enable	VB	0
d	d	JJ	0
-tc	-tc	JJ	0
to	to	TO	0
be	be	VB	0
used	used	VBN	0
as	as	IN	0
a	a	DT	0
molecular	molecular	JJ	B-NP
ruler	ruler	NN	I-NP
to	to	TO	0
determine	determine	VB	0
relative	relative	JJ	B-NP
position	position	NN	I-NP
of	of	IN	0
these	these	DT	0
amino	amino	JJ	0
acids	acids	NNS	0
.	.	.	0
Lerisetron	Lerisetron	JJ	B-NP
inhibition	inhibition	NN	I-NP
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBP	0
binding	binding	VBG	0
to	to	TO	0
mutant	mutant	VB	0
receptor	receptor	NN	B-NP
was	was	VBD	0
also	also	RB	0
investigated	investigated	VBN	0
.	.	.	0
Lerisetron	Lerisetron	NNP	B-NP
is	is	VBZ	0
a	a	DT	0
potent	potent	JJ	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	B-NP
antagonist	antagonist	VBZ	I-NP
first	first	JJ	0
synthesized	synthesized	NN	0
by	by	IN	0
orale	orale	NN	B-NP
et.	et.	NNP	0
al.	al.	NNP	0
[	[	-LRB-	0
28	28	CD	0
]	]	-RRB-	0
.	.	.	0
As	As	RB	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
agonist	agonist	NN	I-NP
,	,	,	0
lerisetron	lerisetron	JJ	B-NP
binding	binding	NN	I-NP
was	was	VBD	0
altered	altered	VBN	0
by	by	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
.	.	.	0
This	This	DT	0
mutation	mutation	NN	0
produced	produced	VBD	0
an	an	DT	0
increase	increase	NN	0
in	in	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
of	of	IN	0
160	160	CD	0
fold	fold	NNS	0
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptor	receptor	NN	B-NP
.	.	.	0
This	This	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
indicates	indicates	VBZ	0
an	an	DT	0
important	important	JJ	0
interaction	interaction	NN	0
of	of	IN	0
lerisetron	lerisetron	NN	B-NP
with	with	IN	0
Y142	Y142	NNP	B-NP
and	and	CC	0
a	a	DT	0
similarity	similarity	NN	0
between	between	IN	0
the	the	DT	0
binding	binding	JJ	0
location	location	NN	0
of	of	IN	0
lerisetron	lerisetron	NN	B-NP
,	,	,	0
5-HT	5-HT	NNP	0
and	and	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
.	.	.	0
Lerisetron	Lerisetron	NNP	B-NP
is	is	VBZ	0
the	the	DT	0
only	only	JJ	0
antagonist	antagonist	NNS	0
tested	tested	VBN	0
that	that	IN	0
shares	shares	NNS	0
a	a	DT	0
binding	binding	JJ	0
site	site	NN	0
interaction	interaction	NN	0
in	in	IN	0
this	this	DT	0
region	region	NN	0
with	with	IN	0
agonist	agonist	NN	B-NP
.	.	.	0
In	In	IN	0
contrast	contrast	NN	0
to	to	TO	0
5-HT	5-HT	CD	0
and	and	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
,	,	,	0
however	however	RB	0
,	,	,	0
lerisetron	lerisetron	VBD	0
also	also	RB	0
interacts	interacts	VBN	0
with	with	IN	0
Y152	Y152	NNP	B-NP
as	as	RB	0
indicated	indicated	VBN	0
by	by	IN	0
the	the	DT	0
190	190	CD	0
fold	fold	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
on	on	FW	0
Y152A	Y152A	FW	0
mutant	mutant	FW	0
receptors	receptors	FW	0
.	.	.	0
Since	Since	IN	0
neither	neither	DT	0
d	d	JJ	0
-tc	-tc	JJ	0
nor	nor	CC	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	0
interacts	interacts	NN	0
with	with	IN	0
Y142	Y142	NNP	B-NP
or	or	CC	0
Y152	Y152	NNP	B-NP
,	,	,	0
there	there	EX	0
appears	appears	VBZ	0
to	to	TO	0
be	be	VB	0
a	a	DT	0
difference	difference	NN	0
between	between	IN	0
the	the	DT	0
interaction	interaction	NN	B-NP
formed	formed	VBN	0
by	by	IN	0
these	these	DT	0
antagonists	antagonists	NN	0
compared	compared	VBN	0
to	to	TO	0
lerisetron	lerisetron	VB	0
.	.	.	0
The	The	DT	0
binding	binding	JJ	0
sites	sites	NNS	0
of	of	IN	0
the	the	DT	0
three	three	CD	0
antagonists	antagonists	NNS	0
tested	tested	VBD	0
differ	differ	VBN	0
with	with	IN	0
respect	respect	NN	0
to	to	TO	0
this	this	DT	0
binding	binding	JJ	0
loop	loop	NN	0
.	.	.	0
Since	Since	IN	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
a	a	DT	0
competitive	competitive	JJ	B-NP
antagonist	antagonist	NN	I-NP
is	is	VBZ	0
simply	simply	RB	0
to	to	TO	0
block	block	VB	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
agonist	agonist	NN	B-NP
and	and	CC	0
prevent	prevent	VB	0
channel	channel	NN	0
opening	opening	NN	0
,	,	,	0
the	the	DT	0
specific	specific	JJ	0
amino	amino	JJ	0
acids	acids	NNS	0
that	that	IN	0
interact	interact	NN	0
with	with	IN	0
the	the	DT	0
ligand	ligand	NN	B-NP
can	can	MD	0
vary	vary	VB	0
for	for	IN	0
different	different	JJ	0
antagonists	antagonists	NNS	0
.	.	.	0
This	This	DT	0
is	is	VBZ	0
less	less	RBR	0
likely	likely	JJ	0
to	to	TO	0
be	be	VB	0
the	the	DT	0
case	case	NN	0
with	with	IN	0
agonist	agonist	NN	B-NP
since	since	IN	0
they	they	PRP	0
must	must	MD	0
produce	produce	VB	0
a	a	DT	0
conformational	conformational	JJ	B-NP
change	change	NN	I-NP
in	in	IN	0
the	the	DT	0
protein	protein	NN	B-NP
to	to	TO	0
exert	exert	VB	0
their	their	PRP$	0
effects	effects	NNS	0
.	.	.	0
Only	Only	RB	0
two	two	CD	0
mutant	mutant	NN	B-NP
receptors	receptors	VBP	0
failed	failed	VBN	0
to	to	TO	0
bind	bind	VB	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
;	;	:	0
G147A	G147A	CD	0
and	and	CC	0
V149A	V149A	NNP	0
.	.	.	0
G147	G147	NNP	B-NP
is	is	VBZ	0
the	the	DT	0
conserved	conserved	JJ	0
glycine	glycine	NN	B-NP
in	in	IN	0
this	this	DT	0
putative	putative	JJ	B-NP
binding	binding	JJ	I-NP
loop	loop	NN	I-NP
.	.	.	0
Chirara	Chirara	NNP	B-NP
et.	et.	NNP	0
al.	al.	NNP	0
have	have	VBP	0
suggested	suggested	VBN	0
that	that	IN	0
the	the	DT	0
highly	highly	RB	0
conserved	conserved	JJ	0
nature	nature	NN	0
of	of	IN	0
the	the	DT	0
glycine	glycine	NN	B-NP
in	in	IN	0
this	this	DT	0
region	region	NN	0
may	may	MD	0
indicate	indicate	VB	0
the	the	DT	0
existence	existence	NN	0
of	of	IN	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
consisting	consisting	VBG	0
of	of	IN	0
either	either	DT	0
γ	γ	NN	0
or	or	CC	0
a	a	DT	0
loose	loose	JJ	0
three	three	CD	0
residue-turn	residue-turn	NN	B-NP
in	in	IN	0
the	the	DT	0
nAChR	nAChR	JJ	0
[	[	-LRB-	0
12	12	CD	0
]	]	-RRB-	0
.	.	.	0
Either	Either	RB	0
of	of	IN	0
these	these	DT	0
turns	turns	NNS	0
would	would	MD	0
bring	bring	VB	0
the	the	DT	0
two	two	CD	0
putative	putative	JJ	B-NP
β-strand	β-strand	NN	I-NP
together	together	RB	0
such	such	JJ	0
that	that	IN	0
γL109	γL109	NNP	B-NP
,	,	,	0
γY111	γY111	NNP	B-NP
and	and	CC	0
γS115	γS115	NNP	B-NP
and	and	CC	0
γY117	γY117	NNP	B-NP
are	are	VBP	0
all	all	RB	0
on	on	IN	0
the	the	DT	0
same	same	JJ	0
side	side	NN	0
of	of	IN	0
an	an	DT	0
antiparallel	antiparallel	JJ	B-NP
β-sheet	β-sheet	NN	I-NP
.	.	.	0
These	These	DT	0
residues	residues	NNS	0
have	have	VBP	0
been	been	VBN	0
identified	identified	VBN	0
by	by	IN	0
affinity	affinity	JJ	B-NP
labeling	labeling	NN	I-NP
,	,	,	0
site-directed	site-directed	JJ	0
mutagenesi	mutagenesi	NN	B-NP
or	or	CC	0
cysteine	cysteine	JJ	B-NP
substitution	substitution	NN	I-NP
to	to	TO	0
lie	lie	VB	0
on	on	IN	0
the	the	DT	0
same	same	JJ	0
surface	surface	NN	0
.	.	.	0
A	A	DT	0
classic	classic	JJ	0
2-residue	2-residue	NNP	0
β-turn	β-turn	NNP	0
would	would	MD	0
place	place	VB	0
these	these	DT	0
residues	residues	NN	0
on	on	IN	0
opposite	opposite	JJ	0
surfaces	surfaces	NNS	0
[	[	-LRB-	0
12	12	CD	0
]	]	-RRB-	0
.	.	.	0
Substitution	Substitution	NNP	B-NP
of	of	IN	0
the	the	DT	0
conserved	conserved	JJ	0
glycine	glycine	NN	B-NP
by	by	IN	0
alanina	alanina	NN	B-NP
may	may	MD	0
disrupt	disrupt	VB	0
the	the	DT	0
structure	structure	NN	0
of	of	IN	0
this	this	DT	0
region	region	NN	0
and	and	CC	0
prevent	prevent	VB	0
assembly	assembly	NN	0
or	or	CC	0
expression	expression	NN	0
of	of	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
.	.	.	0
The	The	DT	0
recent	recent	JJ	0
determination	determination	NN	B-NP
of	of	IN	0
the	the	DT	0
crystal	crystal	NN	0
structure	structure	NN	0
of	of	IN	0
an	an	DT	0
AChBP	AChBP	NN	B-NP
supports	supports	VBZ	0
this	this	DT	0
hypothesis	hypothesis	NN	0
.	.	.	0
The	The	DT	0
achbp	achbp	NN	B-NP
display	display	NN	I-NP
a	a	DT	0
large	large	JJ	0
amount	amount	NN	0
of	of	IN	0
homology	homology	VBG	0
to	to	TO	0
the	the	DT	0
amino	amino	JJ	0
terminal	terminal	NN	0
of	of	IN	0
lgic	lgic	NN	B-NP
receptor	receptor	NN	I-NP
and	and	CC	0
thus	thus	RB	0
may	may	MD	0
be	be	VB	0
similar	similar	JJ	0
in	in	IN	0
structure	structure	NN	0
[	[	-LRB-	0
20	20	CD	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
crystal	crystal	NN	0
structure	structure	NN	0
of	of	IN	0
this	this	DT	0
protein	protein	NN	B-NP
reveals	reveals	VBZ	0
a	a	DT	0
loose	loose	JJ	0
3	3	CD	0
residue	residue	NNS	0
turn	turn	VBP	0
incorporating	incorporating	VBG	0
the	the	DT	0
conserved	conserved	VBN	B-NP
glycine	glycine	NN	I-NP
residue	residue	NN	I-NP
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
homologou	homologou	NN	B-NP
residue	residue	NN	I-NP
in	in	IN	0
other	other	JJ	0
lgic	lgic	NN	B-NP
subunit	subunit	NN	I-NP
have	have	VBP	0
also	also	RB	0
been	been	VBN	0
identified	identified	VBN	0
and	and	CC	0
are	are	VBP	0
shown	shown	VBN	0
in	in	IN	0
Figure	Figure	NNP	0
1	1	CD	0
.	.	.	0
The	The	DT	0
residues	residues	NN	0
identified	identified	VBN	0
in	in	IN	0
this	this	DT	0
study	study	NN	0
as	as	IN	0
altering	altering	VBG	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
of	of	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
would	would	MD	0
also	also	RB	0
be	be	VB	0
present	present	JJ	0
on	on	IN	0
the	the	DT	0
same	same	JJ	0
surface	surface	NN	0
if	if	IN	0
this	this	DT	0
structure	structure	NN	0
is	is	VBZ	0
present	present	JJ	0
in	in	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R.	R.	NNP	0
While	While	IN	0
Y140	Y140	NNP	B-NP
lies	lies	VBZ	0
somewhat	somewhat	RB	0
outside	outside	IN	0
the	the	DT	0
region	region	NN	0
identified	identified	VBN	0
by	by	IN	0
Chiara	Chiara	NNP	0
in	in	IN	0
the	the	DT	0
nAChR	nAChR	JJ	0
(	(	-LRB-	0
homologous	homologous	RB	0
to	to	TO	0
γN107	γN107	CD	B-NP
)	)	-RRB-	0
,	,	,	0
γL109	γL109	NNP	B-NP
and	and	CC	0
γL119	γL119	NNP	B-NP
are	are	VBP	0
homologous	homologous	VBN	0
to	to	TO	0
Y142	Y142	CD	B-NP
and	and	CC	0
Y152	Y152	CD	B-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	NNP	0
3AS	3AS	NNP	0
R.	R.	NNP	0
The	The	DT	0
ability	ability	NN	B-NP
of	of	IN	0
lerisetron	lerisetron	VBG	0
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
both	both	DT	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
also	also	RB	0
supports	supports	VBZ	0
the	the	DT	0
hypothesis	hypothesis	NN	0
that	that	IN	0
these	these	DT	0
two	two	CD	0
amino	amino	CD	0
acids	acids	NNS	0
are	are	VBP	0
present	present	JJ	0
in	in	IN	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
since	since	IN	0
the	the	DT	0
eight	eight	CD	0
intervening	intervening	CD	B-NP
residue	residue	NN	I-NP
would	would	MD	0
position	position	VB	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
too	too	RB	0
far	far	RB	0
apart	apart	RB	0
to	to	TO	0
permit	permit	VB	0
them	them	PRP	0
both	both	VBP	0
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
a	a	DT	0
single	single	JJ	0
ligand	ligand	NN	B-NP
even	even	RB	0
if	if	IN	0
they	they	PRP	0
were	were	VBD	0
interacting	interacting	VBN	0
with	with	IN	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
on	on	IN	0
opposite	opposite	JJ	0
ends	ends	NNS	0
of	of	IN	0
the	the	DT	0
molecule	molecule	NN	B-NP
.	.	.	0
A	A	DT	0
loop	loop	JJ	0
structure	structure	NN	0
would	would	MD	0
bring	bring	VB	0
them	them	PRP	0
into	into	IN	0
closer	closer	JJR	0
proximity	proximity	NNS	0
and	and	CC	0
permit	permit	VB	0
interaction	interaction	VBN	0
with	with	IN	0
the	the	DT	0
small	small	JJ	0
molecule	molecule	NN	B-NP
lerisetron	lerisetron	NN	I-NP
.	.	.	0
All	All	DT	0
three	three	CD	0
tyrosine	tyrosine	CD	B-NP
mutation	mutation	NN	I-NP
were	were	VBD	0
investigated	investigated	VBN	0
using	using	VBG	0
a	a	DT	0
whole	whole	JJ	0
cell	cell	NN	0
patch	patch	NN	0
clamp	clamp	VBZ	0
assay	assay	VBN	0
to	to	TO	0
determine	determine	VB	0
if	if	IN	0
functional	functional	JJ	B-NP
change	change	NN	I-NP
could	could	MD	0
be	be	VB	0
observed	observed	VBN	0
.	.	.	0
Whole	Whole	JJ	0
cell	cell	NN	0
responses	responses	NNS	0
could	could	MD	0
not	not	RB	0
be	be	VB	0
obtained	obtained	VBN	0
for	for	IN	0
Y140A	Y140A	NNP	0
or	or	CC	0
Y142A	Y142A	NNP	0
,	,	,	0
although	although	IN	0
specific	specific	JJ	0
binding	binding	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
was	was	VBD	0
observed	observed	VBN	0
.	.	.	0
These	These	DT	0
data	data	NNS	0
suggest	suggest	VBP	0
that	that	RB	0
,	,	,	0
while	while	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
do	do	VBP	0
assemble	assemble	VBN	0
and	and	CC	0
are	are	VBP	0
capable	capable	JJ	0
of	of	IN	0
binding	binding	JJ	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
,	,	,	0
they	they	PRP	0
are	are	VBP	0
either	either	RB	0
not	not	RB	0
transported	transported	VBN	0
to	to	TO	0
the	the	DT	0
cell	cell	NN	0
surface	surface	NN	0
or	or	CC	0
are	are	VBP	0
non-responsive	non-responsive	JJ	B-NP
to	to	TO	0
5-HT	5-HT	CD	0
at	at	IN	0
concentration	concentration	NN	B-NP
of	of	IN	0
1	1	CD	0
mM	mM	JJ	0
or	or	CC	0
less	less	JJR	0
.	.	.	0
Y152A	Y152A	NNP	0
does	does	VBZ	0
produce	produce	VB	0
functional	functional	JJ	B-NP
channel	channel	NN	I-NP
however	however	RB	0
they	they	PRP	0
display	display	VBP	0
distinctly	distinctly	RB	0
altered	altered	VBN	B-NP
response	response	NN	I-NP
kinetics	kinetics	NN	I-NP
when	when	WRB	0
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptor	receptor	NN	B-NP
.	.	.	0
Y152A	Y152A	NNP	0
responses	responses	NNS	0
do	do	VBP	0
not	not	RB	0
show	show	VB	0
the	the	DT	0
rapid	rapid	JJ	B-NP
rise	rise	NN	I-NP
time	time	NN	I-NP
observed	observed	VBD	0
in	in	IN	0
wt	wt	JJ	B-NP
receptor	receptor	NN	I-NP
.	.	.	0
The	The	DT	0
extremely	extremely	RB	0
slow	slow	JJ	0
rise	rise	NN	B-NP
time	time	NN	I-NP
observed	observed	VBD	0
for	for	IN	0
Y152A	Y152A	CD	0
receptors	receptors	NNS	0
may	may	MD	0
indicate	indicate	VB	0
a	a	DT	0
change	change	NN	0
in	in	IN	0
rate	rate	NN	B-NP
constant	constant	JJ	I-NP
preceding	preceding	VBG	0
channel	channel	NN	0
opening	opening	NN	0
.	.	.	0
These	These	DT	0
changes	changes	NNS	0
in	in	IN	0
the	the	DT	0
rate	rate	NN	B-NP
constant	constant	JJ	I-NP
for	for	IN	0
either	either	DT	0
agonist	agonist	JJ	B-NP
binding	binding	NN	I-NP
or	or	CC	0
channel	channel	VB	0
opening	opening	VBG	0
also	also	RB	0
produce	produce	VB	0
a	a	DT	0
140	140	CD	0
fold	fold	JJ	0
decrease	decrease	NN	0
in	in	IN	0
the	the	DT	0
observed	observed	JJ	0
EC	EC	NNP	B-NP
50	50	CD	0
for	for	IN	0
5-HT	5-HT	CD	0
activation	activation	NNS	0
.	.	.	0
The	The	DT	0
slow	slow	JJ	0
rise	rise	NN	0
is	is	VBZ	0
followed	followed	VBN	0
by	by	IN	0
a	a	DT	0
non-desensitizing	non-desensitizing	JJ	B-NP
phase	phase	NN	I-NP
of	of	IN	0
the	the	DT	0
response	response	NN	0
that	that	WDT	0
is	is	VBZ	0
dramatically	dramatically	RB	0
different	different	JJ	0
from	from	IN	0
the	the	DT	0
fast	fast	JJ	0
desensitization	desensitization	NN	B-NP
observed	observed	VBD	0
for	for	IN	0
wt	wt	JJ	0
5-HT	5-HT	NNP	0
3AS	3AS	NNP	0
Rs	Rs	NNP	0
.	.	.	0
Lack	Lack	NN	0
of	of	IN	0
desensitization	desensitization	NN	B-NP
could	could	MD	0
result	result	VB	0
from	from	IN	0
either	either	RB	0
a	a	DT	0
stabilization	stabilization	NN	B-NP
of	of	IN	0
the	the	DT	0
open	open	JJ	0
state	state	NN	0
of	of	IN	0
the	the	DT	0
channel	channel	NN	0
or	or	CC	0
a	a	DT	0
destabilization	destabilization	NN	B-NP
of	of	IN	0
the	the	DT	0
desensitized	desensitized	JJ	0
state	state	NN	0
.	.	.	0
Mutations	Mutations	NNS	0
of	of	IN	0
homologous	homologous	NN	B-NP
or	or	CC	0
nearby	nearby	JJ	0
residues	residues	NNS	0
in	in	IN	0
both	both	PDT	0
the	the	DT	0
nAChR	nAChR	JJ	0
and	and	CC	0
GABA	GABA	NNP	B-NP
A	A	NNP	0
receptor	receptor	NN	B-NP
have	have	VBP	0
also	also	RB	0
been	been	VBN	0
demonstrated	demonstrated	VBN	0
to	to	TO	0
alter	alter	VB	0
the	the	DT	0
agonist	agonist	JJ	B-NP
response	response	NN	I-NP
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
the	the	DT	0
homologous	homologous	JJ	B-NP
residue	residue	NN	I-NP
in	in	IN	0
the	the	DT	0
GABA	GABA	NNP	B-NP
A	A	DT	0
receptor	receptor	NN	B-NP
γ-subunit	γ-subunit	NN	I-NP
(	(	-LRB-	0
T142	T142	NNP	B-NP
)	)	-RRB-	0
to	to	TO	0
serine	serine	VB	0
altered	altered	VBN	0
the	the	DT	0
efficacy	efficacy	NN	0
of	of	IN	0
the	the	DT	0
agonist	agonist	JJ	B-NP
Flumazenil	Flumazenil	NNP	I-NP
,	,	,	0
converting	converting	VBG	0
it	it	PRP	0
to	to	TO	0
a	a	DT	0
partial	partial	JJ	0
agonist	agonist	NN	B-NP
[	[	-LRB-	0
29	29	CD	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
the	the	DT	0
nAChR	nAChR	JJ	0
,	,	,	0
mutation	mutation	NN	0
of	of	IN	0
mouse	mouse	NN	0
and	and	CC	0
rat	rat	CD	B-NP
εP121	εP121	CD	I-NP
to	to	TO	0
leucine	leucine	VB	0
altered	altered	VBN	0
both	both	PDT	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
acetylcholine	acetylcholine	NN	B-NP
and	and	CC	0
the	the	DT	0
stability	stability	NN	0
of	of	IN	0
the	the	DT	0
open	open	JJ	0
state	state	NN	0
of	of	IN	0
the	the	DT	0
channel.	channel.	NNP	0
εP121	εP121	NNP	B-NP
is	is	VBZ	0
homologous	homologous	VBN	0
to	to	TO	0
P154	P154	CD	B-NP
in	in	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
and	and	CC	0
is	is	VBZ	0
only	only	RB	0
two	two	CD	0
residues	residues	NNS	0
away	away	RB	0
from	from	IN	0
Y152	Y152	CD	B-NP
.	.	.	0
The	The	DT	0
authors	authors	NNS	0
of	of	IN	0
this	this	DT	0
study	study	NN	0
concluded	concluded	VBD	0
that	that	IN	0
this	this	DT	0
portion	portion	NN	0
of	of	IN	0
the	the	DT	0
acetylcholine	acetylcholine	JJ	B-NP
binding	binding	JJ	I-NP
site	site	NN	I-NP
was	was	VBD	0
closely	closely	RB	0
linked	linked	VBN	0
to	to	TO	0
the	the	DT	0
channel	channel	NN	0
opening	opening	NN	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
[	[	-LRB-	0
30	30	CD	0
]	]	-RRB-	0
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
reasonable	reasonable	JJ	0
to	to	TO	0
conclude	conclude	VB	0
that	that	IN	0
the	the	DT	0
homologous	homologous	JJ	B-NP
region	region	NN	I-NP
in	in	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
may	may	MD	0
perform	perform	VB	0
a	a	DT	0
similar	similar	JJ	0
function	function	NN	0
.	.	.	0
The	The	DT	0
link	link	NN	0
between	between	IN	0
an	an	DT	0
agonist	agonist	JJ	B-NP
binding	binding	JJ	I-NP
domain	domain	NN	I-NP
and	and	CC	0
a	a	DT	0
conformational	conformational	JJ	B-NP
change	change	NN	I-NP
leading	leading	VBG	0
to	to	TO	0
channel	channel	VB	0
opening	opening	NN	0
is	is	VBZ	0
not	not	RB	0
unexpected	unexpected	JJ	0
since	since	IN	0
the	the	DT	0
two	two	CD	0
must	must	MD	0
obviously	obviously	RB	0
be	be	VB	0
linked	linked	VBN	0
.	.	.	0
If	If	IN	0
binding	binding	VBG	0
to	to	TO	0
this	this	DT	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
is	is	VBZ	0
shown	shown	VBN	0
to	to	TO	0
be	be	VB	0
a	a	DT	0
critical	critical	JJ	B-NP
step	step	NN	I-NP
between	between	IN	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
agonist	agonist	NN	B-NP
and	and	CC	0
the	the	DT	0
opening	opening	NN	0
of	of	IN	0
the	the	DT	0
channel	channel	NN	0
,	,	,	0
further	further	JJ	0
investigation	investigation	NN	B-NP
of	of	IN	0
the	the	DT	0
amino	amino	JJ	0
acids	acids	NNS	0
in	in	IN	0
this	this	DT	0
loop	loop	NN	0
may	may	MD	0
provide	provide	VB	0
valuable	valuable	JJ	0
clues	clues	NNS	0
to	to	TO	0
molecular	molecular	JJ	B-NP
basis	basis	NN	I-NP
of	of	IN	0
this	this	DT	0
process	process	NN	0
.	.	.	0
Conclusions	Conclusions	VBG	0
Our	Our	PRP$	0
data	data	NNS	0
indicate	indicate	VBP	0
an	an	DT	0
important	important	JJ	0
role	role	NN	0
for	for	IN	0
this	this	DT	0
putative	putative	JJ	B-NP
binding	binding	JJ	I-NP
site	site	NN	I-NP
loop	loop	NN	I-NP
in	in	IN	0
the	the	DT	0
interaction	interaction	NN	0
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
with	with	IN	0
different	different	JJ	0
ligand	ligand	NN	B-NP
and	and	CC	0
illustrate	illustrate	VB	0
the	the	DT	0
difference	difference	NN	0
in	in	IN	0
binding	binding	VBG	0
of	of	IN	0
different	different	JJ	0
ligand	ligand	NN	B-NP
structural	structural	JJ	I-NP
class	class	NN	I-NP
.	.	.	0
Each	Each	DT	0
structural	structural	JJ	B-NP
class	class	NN	I-NP
shows	shows	VBZ	0
different	different	JJ	0
patterns	patterns	NNS	0
of	of	IN	0
interaction	interaction	NN	0
with	with	IN	0
amino	amino	JJ	0
acids	acids	NNS	0
in	in	IN	0
this	this	DT	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
receptor.	receptor.	NNP	B-NP
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
does	does	VBZ	0
not	not	RB	0
appear	appear	VB	0
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
amino	amino	JJ	0
acids	acids	NNS	0
tested	tested	VBN	0
while	while	IN	0
d	d	JJ	0
-tc	-tc	JJ	0
interacts	interacts	NN	0
with	with	IN	0
only	only	RB	0
Y140	Y140	CD	B-NP
,	,	,	0
m	m	VBG	0
CPBG	CPBG	NNP	B-NP
and	and	CC	0
5-HT	5-HT	CD	0
with	with	IN	0
Y142	Y142	NNP	B-NP
and	and	CC	0
lerisetron	lerisetron	NN	B-NP
with	with	IN	0
both	both	DT	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
.	.	.	0
similar	similar	JJ	B-NP
selective	selective	JJ	I-NP
effect	effect	NN	I-NP
have	have	VBP	0
been	been	VBN	0
observed	observed	VBN	0
on	on	IN	0
other	other	JJ	0
residues	residues	NNS	0
including	including	VBG	B-NP
W183	W183	NNP	I-NP
,	,	,	0
W89	W89	NNP	B-NP
,	,	,	0
F107	F107	NNP	B-NP
and	and	CC	0
E106	E106	CD	B-NP
among	among	IN	0
others	others	NNS	0
[	[	-LRB-	0
20	20	CD	0
21	21	CD	0
25	25	CD	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
Our	Our	PRP$	0
data	data	NNS	0
in	in	IN	0
conjunction	conjunction	NN	0
with	with	IN	0
those	those	DT	0
of	of	IN	0
other	other	JJ	0
laboratories	laboratories	NNS	0
indicates	indicates	VBZ	0
the	the	DT	0
differences	differences	NNS	0
in	in	IN	0
orientation	orientation	NN	0
of	of	IN	0
different	different	JJ	0
ligand	ligand	NN	B-NP
within	within	IN	0
the	the	DT	0
same	same	JJ	0
binding	binding	JJ	0
cleft	cleft	NN	0
.	.	.	0
These	These	DT	0
differences	differences	NNS	0
in	in	IN	0
orientation	orientation	JJ	B-NP
result	result	NN	I-NP
in	in	IN	0
different	different	JJ	0
amino	amino	JJ	0
acid/functional	acid/functional	NN	B-NP
group	group	NN	I-NP
interaction	interaction	NN	I-NP
.	.	.	0
As	As	IN	0
the	the	DT	0
structural	structural	JJ	B-NP
detail	detail	NN	I-NP
of	of	IN	0
these	these	DT	0
interaction	interaction	NN	B-NP
emerges	emerges	VBZ	0
,	,	,	0
these	these	DT	0
differences	differences	NNS	0
could	could	MD	0
potentially	potentially	RB	0
be	be	VB	0
exploited	exploited	VBN	0
to	to	TO	0
produce	produce	VB	0
more	more	RBR	0
potent	potent	JJ	0
and	and	CC	0
specific	specific	JJ	0
ligand	ligand	NN	B-NP
.	.	.	0
For	For	IN	0
example	example	NN	B-NP
construction	construction	NN	I-NP
of	of	IN	0
a	a	DT	0
"hybrid	"hybrid	NN	0
"	"	''	0
ligand	ligand	NN	B-NP
that	that	WDT	0
combines	combines	VBZ	0
the	the	DT	0
interaction	interaction	NN	B-NP
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
with	with	IN	0
those	those	DT	0
of	of	IN	0
d	d	JJ	0
-tc	-tc	NN	0
,	,	,	0
5-HT	5-HT	NNP	0
or	or	CC	0
m	m	JJ	B-NP
CPBG	CPBG	NNP	I-NP
could	could	MD	0
produce	produce	VB	0
an	an	DT	0
antagonist	antagonist	NN	0
with	with	IN	0
increased	increased	JJ	0
affinity	affinity	JJ	B-NP
due	due	JJ	0
to	to	TO	0
the	the	DT	0
additional	additional	JJ	0
binding	binding	JJ	0
energy	energy	NN	B-NP
of	of	IN	0
these	these	DT	0
interaction	interaction	NN	B-NP
and	and	CC	0
a	a	DT	0
greater	greater	JJR	0
specificity	specificity	NN	0
since	since	IN	0
it	it	PRP	0
would	would	MD	0
utilize	utilize	VB	0
more	more	RBR	0
structural	structural	JJ	B-NP
feature	feature	NN	I-NP
of	of	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
.	.	.	0
The	The	DT	0
requirement	requirement	NN	0
of	of	IN	0
a	a	DT	0
glycine	glycine	NN	B-NP
at	at	IN	0
position	position	NN	0
147	147	CD	0
and	and	CC	0
the	the	DT	0
ability	ability	NN	B-NP
of	of	IN	0
lerisetron	lerisetron	VBG	0
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
both	both	DT	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
also	also	RB	0
support	support	VB	0
the	the	DT	0
hypothesis	hypothesis	NN	0
that	that	IN	0
the	the	DT	0
secondary	secondary	JJ	B-NP
structure	structure	NN	I-NP
in	in	IN	0
this	this	DT	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
is	is	VBZ	0
formed	formed	VBN	0
by	by	IN	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
.	.	.	0
If	If	IN	0
the	the	DT	0
loose	loose	JJ	0
3	3	CD	0
residue	residue	NNS	0
turn	turn	VBP	0
proposed	proposed	VBN	0
by	by	IN	0
Chiara	Chiara	NNP	0
et.	et.	NNP	0
al.	al.	NNP	0
and	and	CC	0
shown	shown	VBN	0
for	for	IN	0
the	the	DT	0
AChBP	AChBP	NN	B-NP
is	is	VBZ	0
present	present	JJ	0
in	in	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
,	,	,	0
then	then	RB	0
Y140	Y140	CD	B-NP
,	,	,	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
would	would	MD	0
be	be	VB	0
present	present	JJ	0
on	on	IN	0
the	the	DT	0
same	same	JJ	0
side	side	NN	0
of	of	IN	0
the	the	DT	0
sheet	sheet	NN	0
and	and	CC	0
all	all	DT	0
three	three	CD	0
would	would	MD	0
be	be	VB	0
capable	capable	JJ	0
of	of	IN	0
extending	extending	VBG	0
into	into	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
.	.	.	0
A	A	DT	0
similar	similar	JJ	0
observation	observation	NN	0
has	has	VBZ	0
been	been	VBN	0
made	made	VBN	0
for	for	IN	0
the	the	DT	0
nAChR	nAChR	JJ	0
where	where	WRB	0
γS111	γS111	NNP	B-NP
,	,	,	0
γY117	γY117	NNP	B-NP
,	,	,	0
γL119	γL119	NNP	B-NP
,	,	,	0
δR113	δR113	NNP	B-NP
and	and	CC	0
δT119	δT119	CD	B-NP
of	of	IN	0
the	the	DT	0
mouse	mouse	JJ	0
nAChR	nAChR	JJ	B-NP
receptor	receptor	NN	I-NP
and	and	CC	0
γL109	γL109	NNP	B-NP
and	and	CC	0
torpedo	torpedo	JJ	B-NP
nachr	nachr	NN	I-NP
γy111	γy111	NN	I-NP
are	are	VBP	0
all	all	RB	0
thought	thought	VBN	0
to	to	TO	0
be	be	VB	0
present	present	JJ	0
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
[	[	-LRB-	0
12	12	CD	0
13	13	CD	0
14	14	CD	0
15	15	CD	0
16	16	CD	0
17	17	CD	0
18	18	CD	0
]	]	-RRB-	0
.	.	.	0
Materials	Materials	NNS	0
and	and	CC	0
Methods	Methods	NNP	0
Materials	Materials	NNPS	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	0
was	was	VBD	0
purchased	purchased	VBN	0
from	from	IN	0
New	New	NNP	0
England	England	NNP	0
Nuclear	Nuclear	NNP	0
,	,	,	0
5-HT	5-HT	NNP	0
from	from	IN	0
Spectrum	Spectrum	NNP	0
,	,	,	0
and	and	CC	0
m	m	JJ	0
CPBG	CPBG	NNP	0
and	and	CC	0
d	d	JJ	0
-tc	-tc	NN	0
from	from	IN	0
Research	Research	NNP	0
Biochemical	Biochemical	NNP	0
International	International	NNP	0
.	.	.	0
Lerisetron	Lerisetron	NNP	0
was	was	VBD	0
provided	provided	VBN	0
by	by	IN	0
Dr.	Dr.	NNP	0
Karen	Karen	NNP	0
Kirschbaum	Kirschbaum	NNP	0
at	at	IN	0
The	The	DT	0
University	University	NNP	0
of	of	IN	0
Louisiana	Louisiana	NNP	0
at	at	IN	0
Monroe	Monroe	NNP	0
,	,	,	0
Monroe	Monroe	NNP	0
,	,	,	0
LA	LA	NNP	0
.	.	.	0
All	All	DT	0
other	other	JJ	0
reagents	reagents	NN	0
were	were	VBD	0
obtained	obtained	VBN	0
from	from	IN	0
commercial	commercial	JJ	0
sources	sources	NNS	0
.	.	.	0
Site	Site	FW	0
directed	directed	VBN	B-NP
mutagenesi	mutagenesi	NN	I-NP
Wild	Wild	FW	0
type	type	FW	0
5-HT	5-HT	FW	0
3AS	3AS	FW	0
mouse	mouse	FW	0
receptor	receptor	FW	0
cDNA	cDNA	NNP	0
was	was	VBD	0
obtained	obtained	VBN	0
from	from	IN	0
Dr.	Dr.	NNP	B-NP
Michael	Michael	NNP	0
White	White	NNP	0
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
mutant	mutant	NN	B-NP
receptor	receptor	NN	I-NP
were	were	VBD	0
constructed	constructed	VBN	0
using	using	VBG	0
either	either	RB	0
the	the	DT	0
Quick	Quick	NNP	0
Change	Change	NNP	B-NP
Mutagenesis	Mutagenesis	NNP	I-NP
kit	kit	NN	I-NP
(	(	-LRB-	0
Stratagene	Stratagene	NNP	B-NP
)	)	-RRB-	0
or	or	CC	0
the	the	DT	0
Altered	Altered	NNP	0
Sites	Sites	NNP	0
Mutagenesis	Mutagenesis	NNP	B-NP
kit	kit	NN	I-NP
(	(	-LRB-	0
Promega	Promega	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
All	All	DT	0
mutations	mutations	NN	0
were	were	VBD	0
confirmed	confirmed	VBN	0
by	by	IN	0
commercial	commercial	JJ	B-NP
DNA	DNA	NN	I-NP
sequencing	sequencing	NN	I-NP
.	.	.	0
Cell	Cell	NN	0
culture	culture	NN	0
and	and	CC	0
transfection	transfection	CD	0
tsA201	tsA201	CD	0
cells	cells	NNS	0
,	,	,	0
a	a	DT	0
derivative	derivative	JJ	0
of	of	IN	0
HEK293	HEK293	CD	0
cells	cells	NNS	0
,	,	,	0
were	were	VBD	0
seeded	seeded	VBN	0
at	at	IN	0
a	a	DT	0
density	density	NN	0
of	of	IN	0
5	5	CD	0
×	×	CD	0
10	10	CD	0
6cells	6cells	CD	0
/	/	CD	0
100	100	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
grown	grown	VBN	0
in	in	IN	0
DMEM	DMEM	NNP	0
medium	medium	NN	0
containing	containing	VBG	0
10	10	CD	0
%	%	NN	0
FBS	FBS	NNP	0
,	,	,	0
100	100	CD	0
units	units	NNS	0
/	/	SYM	0
ml	ml	FW	0
penicillin	penicillin	FW	0
/	/	FW	0
streptomycin	streptomycin	FW	0
for	for	IN	0
nine	nine	CD	0
hours	hours	NNS	0
in	in	IN	0
5	5	CD	0
%	%	NN	0
CO	CO	NNP	0
2	2	CD	0
and	and	CC	0
transfected	transfected	NN	0
with	with	IN	0
10	10	CD	0
μg	μg	CD	0
mouse	mouse	CD	0
5-HT	5-HT	CD	0
3AS	3AS	CD	0
R	R	NN	0
cDNA	cDNA	NN	0
per	per	IN	0
100	100	CD	0
mm	mm	NNS	0
dish	dish	VBP	0
using	using	VBG	0
the	the	DT	0
calcium	calcium	JJ	0
phosphate	phosphate	JJ	0
technique	technique	NN	0
(	(	-LRB-	0
New	New	NNP	0
Life	Life	NNP	0
Technologies	Technologies	NNPS	0
,	,	,	0
NY	NY	NNP	0
)	)	-RRB-	0
.	.	.	0
Media	Media	NNS	0
was	was	VBD	0
changed	changed	VBN	0
12-14	12-14	CD	0
hrs	hrs	NN	0
after	after	IN	0
transfection	transfection	NN	0
.	.	.	0
The	The	DT	0
cells	cells	NNS	0
were	were	VBD	0
allowed	allowed	VBN	0
to	to	TO	0
grow	grow	VB	0
for	for	IN	0
another	another	DT	0
24	24	CD	0
hours	hours	NNS	0
and	and	CC	0
then	then	RB	0
harvested	harvested	VBN	0
.	.	.	0
For	For	IN	0
whole	whole	JJ	0
cell	cell	NN	0
patch	patch	NN	0
clamp	clamp	NN	0
experiments	experiments	NNS	0
,	,	,	0
tsa201	tsa201	NN	B-NP
cell	cell	NN	I-NP
were	were	VBD	0
seeded	seeded	VBN	0
to	to	TO	0
a	a	DT	0
density	density	NN	0
of	of	IN	0
0.25	0.25	CD	0
×	×	CD	0
10	10	CD	0
6cells	6cells	CD	0
/	/	CD	0
60	60	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
grown	grown	VBN	0
in	in	IN	0
DMEM	DMEM	NNP	B-NP
culture	culture	NN	I-NP
medium	medium	NN	I-NP
containing	containing	VBG	0
10	10	CD	0
%	%	NN	0
fetal	fetal	JJ	B-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
bovine	bovine	JJ	I-NP
serum	serum	NN	I-NP
and	and	CC	0
100	100	CD	0
unit	unit	NN	B-NP
/	/	SYM	I-NP
ml	ml	NN	I-NP
penicillin	penicillin	NN	I-NP
/	/	NN	I-NP
streptomycin	streptomycin	NN	I-NP
for	for	IN	0
12	12	CD	0
hours	hours	NNS	0
prior	prior	RB	0
to	to	TO	0
transfection	transfection	VB	0
.	.	.	0
transfection	transfection	NN	B-NP
were	were	VBD	0
performed	performed	VBN	0
using	using	VBG	0
Superfect	Superfect	NNP	B-NP
Transfection	Transfection	NNP	I-NP
Reagent	Reagent	NNP	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
,	,	,	0
CA	CA	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
Ten	Ten	CD	0
cdna	cdna	NN	B-NP
μg	μg	NN	I-NP
were	were	VBD	0
mixed	mixed	VBN	0
with	with	IN	0
DMEM	DMEM	NNP	B-NP
medium	medium	NN	I-NP
containing	containing	VBG	0
no	no	DT	0
serum	serum	NN	B-NP
or	or	CC	0
antibiotics	antibiotics	NN	0
in	in	IN	0
a	a	DT	0
volume	volume	NN	0
of	of	IN	0
150	150	CD	0
μl	μl	NN	B-NP
.	.	.	0
Twenty	Twenty	CD	0
superfect	superfect	NN	B-NP
reagent	reagent	NN	I-NP
μl	μl	NN	I-NP
were	were	VBD	0
then	then	RB	0
added	added	VBN	0
and	and	CC	0
the	the	DT	0
mixture	mixture	NN	B-NP
incubated	incubated	NN	I-NP
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
for	for	IN	0
15	15	CD	0
min	min	NN	B-NP
.	.	.	0
The	The	DT	0
reaction	reaction	NN	0
was	was	VBD	0
terminated	terminated	VBN	0
by	by	IN	0
adding	adding	VBG	0
1	1	CD	0
ml	ml	NN	0
of	of	IN	0
DMEM	DMEM	NNP	B-NP
medium	medium	NN	I-NP
containing	containing	VBG	0
10	10	CD	0
%	%	NN	0
fetal	fetal	JJ	B-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
bovine	bovine	JJ	I-NP
serum	serum	NN	I-NP
and	and	CC	0
100	100	CD	0
unit	unit	NN	B-NP
/	/	SYM	I-NP
ml	ml	NN	I-NP
penicillin	penicillin	NN	I-NP
/	/	NN	I-NP
streptomycin	streptomycin	NN	I-NP
and	and	CC	0
the	the	DT	0
entire	entire	JJ	0
mixture	mixture	NN	0
added	added	VBD	0
to	to	TO	0
cells	cells	NNS	0
in	in	IN	0
the	the	DT	0
60	60	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
exposed	exposed	VBN	0
to	to	TO	0
Superfect	Superfect	NNP	B-NP
Reagent	Reagent	NNP	I-NP
for	for	IN	0
3	3	CD	0
hours	hours	NNS	0
.	.	.	0
At	At	IN	0
that	that	DT	0
time	time	NN	0
,	,	,	0
the	the	DT	0
reagent	reagent	NN	B-NP
was	was	VBD	0
replaced	replaced	VBN	0
with	with	IN	0
DMEM	DMEM	NNP	B-NP
medium	medium	NN	I-NP
containing	containing	VBG	0
10	10	CD	0
%	%	NN	0
fetal	fetal	JJ	B-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
bovine	bovine	JJ	I-NP
serum	serum	NN	I-NP
and	and	CC	0
100	100	CD	0
unit	unit	NN	B-NP
/	/	SYM	I-NP
ml	ml	NN	I-NP
penicillin	penicillin	NN	I-NP
/	/	NN	I-NP
streptomycin	streptomycin	NN	I-NP
and	and	CC	0
incubated	incubated	NN	0
for	for	IN	0
an	an	DT	0
additional	additional	JJ	0
24	24	CD	0
hours	hours	NNS	0
prior	prior	RB	0
to	to	TO	0
use	use	VB	0
.	.	.	0
Binding	Binding	JJ	0
assays	assays	JJ	0
transfected	transfected	NN	B-NP
cell	cell	NN	I-NP
were	were	VBD	0
scraped	scraped	VBN	0
from	from	IN	0
the	the	DT	0
dishes	dishes	NNS	0
,	,	,	0
washed	washed	VBD	0
twice	twice	RB	0
with	with	IN	0
Dulbecco	Dulbecco	NNP	0
's	's	POS	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
(	(	-LRB-	0
New	New	NNP	0
Life	Life	NNP	0
Technologies	Technologies	NNPS	0
,	,	,	0
NY	NY	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
then	then	RB	0
resuspended	resuspended	VBN	0
in	in	IN	0
1.0	1.0	CD	0
ml	ml	JJ	B-NP
ice	ice	NN	I-NP
cold	cold	JJ	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
/	/	CD	0
100	100	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
either	either	RB	0
used	used	VBN	0
fresh	fresh	JJ	0
or	or	CC	0
frozen	frozen	VBN	0
at	at	IN	0
this	this	DT	0
step	step	NN	0
until	until	IN	0
needed	needed	VBN	0
.	.	.	0
Immediately	Immediately	RB	0
prior	prior	RB	0
to	to	TO	0
use	use	VB	0
,	,	,	0
cells	cells	NNS	0
were	were	VBD	0
homogenized	homogenized	VBN	B-NP
on	on	IN	0
ice	ice	NN	0
in	in	IN	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
using	using	VBG	0
a	a	DT	0
glass	glass	NN	0
tissue	tissue	NN	0
homogenizer	homogenizer	VBZ	0
then	then	RB	0
centrifuged	centrifuged	VBN	0
at	at	IN	0
35	35	CD	0
000	000	CD	0
×	×	CD	0
g	g	NN	0
for	for	IN	0
30	30	CD	0
minutes	minutes	NNS	0
in	in	IN	0
a	a	DT	0
Beckman	Beckman	NNP	B-NP
JA20	JA20	NN	I-NP
rotor	rotor	NN	I-NP
(	(	-LRB-	0
4°C	4°C	NNP	0
)	)	-RRB-	0
.	.	.	0
Membranes	Membranes	NNP	0
were	were	VBD	0
washed	washed	VBN	0
once	once	RB	0
more	more	JJR	0
with	with	IN	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
at	at	IN	0
4°C	4°C	NNP	0
then	then	RB	0
resuspended	resuspended	VBN	0
in	in	IN	0
1	1	CD	0
ml	ml	JJ	B-NP
pb	pb	NN	I-NP
/	/	CD	0
100	100	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Protein	Protein	NN	0
content	content	NN	0
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
a	a	DT	0
Lowry	Lowry	JJ	0
assay	assay	NNS	0
(	(	-LRB-	0
Sigma	Sigma	NNP	0
.	.	.	0
Diagnostics	Diagnostics	NNP	0
,	,	,	0
St.	St.	NNP	0
Louis	Louis	NNP	0
,	,	,	0
MO	MO	NNP	0
)	)	-RRB-	0
.	.	.	0
Membranes	Membranes	NNP	0
were	were	VBD	0
initially	initially	RB	0
prepared	prepared	VBN	0
and	and	CC	0
B	B	NNP	0
max	max	NN	0
and	and	CC	0
K	K	NNP	0
d	d	SYM	0
values	values	VBZ	0
determined	determined	VBN	0
in	in	IN	0
the	the	DT	0
presence	presence	NN	0
and	and	CC	0
absence	absence	NN	0
of	of	IN	0
a	a	DT	0
cocktail	cocktail	NN	0
of	of	IN	0
protease	protease	JJ	0
inhibitors	inhibitors	NNS	0
(	(	-LRB-	0
Complete	Complete	NNP	0
Protease	Protease	NNP	0
Inhibitor	Inhibitor	NNP	0
Cocktail	Cocktail	NNP	0
,	,	,	0
Roche	Roche	NNP	0
Diagnostics	Diagnostics	NNPS	0
,	,	,	0
Mannheim	Mannheim	NNP	0
Germany	Germany	NNP	0
)	)	-RRB-	0
.	.	.	0
No	No	DT	0
change	change	NN	0
in	in	IN	0
B	B	NNP	0
max	max	NN	0
was	was	VBD	0
observed	observed	VBN	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
omitting	omitting	VBG	0
the	the	DT	0
protease	protease	JJ	0
inhibitor	inhibitor	NNS	0
(	(	-LRB-	0
B	B	NNP	0
max	max	NNS	0
(	(	-LRB-	0
+	+	FW	0
protease	protease	FW	0
inhibitor	inhibitor	FW	0
)	)	-RRB-	0
=	=	SYM	0
3.1	3.1	FW	0
±	±	FW	0
0.11	0.11	FW	0
pmoles	pmoles	FW	0
/	/	FW	0
mg	mg	FW	0
protein	protein	FW	0
vs	vs	FW	0
B	B	NNP	0
max	max	NNS	0
(	(	-LRB-	0
-	-	FW	0
protease	protease	FW	0
inhibitor	inhibitor	FW	0
)	)	-RRB-	0
=	=	SYM	0
3.2	3.2	CD	0
±	±	CD	0
0.13	0.13	CD	0
pmoles	pmoles	CD	0
/	/	CD	0
mg	mg	CD	0
protein.	protein.	CD	0
)	)	-RRB-	0
hence	hence	RB	0
all	all	DT	0
assays	assays	NN	0
were	were	VBD	0
performed	performed	VBN	0
in	in	IN	0
the	the	DT	0
absence	absence	NN	0
of	of	IN	0
the	the	DT	0
cocktail	cocktail	NN	0
.	.	.	0
Binding	Binding	JJ	0
assays	assays	NN	0
were	were	VBD	0
performed	performed	VBN	0
in	in	IN	0
PBS	PBS	NNP	0
.	.	.	0
For	For	IN	0
K	K	NNP	0
d	d	SYM	0
determinations	determinations	FW	0
,	,	,	0
100	100	CD	0
μl	μl	NN	0
of	of	IN	0
homogenate	homogenate	NN	0
was	was	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
1	1	CD	0
hour	hour	NN	0
with	with	IN	0
varying	varying	VBG	0
concentrations	concentrations	NNS	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NNS	0
(	(	-LRB-	0
NEN	NEN	NNP	0
,	,	,	0
MA	MA	NNP	0
)	)	-RRB-	0
.	.	.	0
Specific	Specific	JJ	0
binding	binding	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	0
was	was	VBD	0
determined	determined	VBN	0
as	as	IN	0
the	the	DT	0
bound	bound	NN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
not	not	RB	0
displaced	displaced	VBN	0
by	by	IN	0
a	a	DT	0
saturating	saturating	JJ	0
concentration	concentration	NN	0
of	of	IN	0
a	a	DT	0
competing	competing	JJ	0
ligand	ligand	NN	0
.	.	.	0
K	K	NNP	0
d	d	NN	0
values	values	NNS	0
were	were	VBD	0
determined	determined	VBN	0
by	by	IN	0
fitting	fitting	VBG	0
the	the	DT	0
binding	binding	JJ	0
data	data	NNS	0
to	to	TO	0
the	the	DT	0
following	following	JJ	0
equation	equation	NN	0
using	using	VBG	0
Graphpad	Graphpad	NNP	0
PRISM	PRISM	NNP	0
(	(	-LRB-	0
San	San	NNP	0
Diego	Diego	NNP	0
CA	CA	NNP	0
)	)	-RRB-	0
:	:	:	0
B	B	NNP	0
=	=	NNP	0
B	B	NNP	0
max	max	NNS	0
[	[	-LRB-	0
L	L	NNP	0
]	]	-RRB-	0
n	n	FW	0
/	/	FW	0
(	(	-LRB-	0
[	[	-LRB-	0
L	L	NNP	0
]	]	-RRB-	0
n+	n+	NNP	0
K	K	NNP	0
n	n	CD	0
)	)	-RRB-	0
,	,	,	0
where	where	WRB	0
B	B	NNP	0
is	is	VBZ	0
bound	bound	VBN	0
ligand	ligand	NN	0
,	,	,	0
B	B	NNP	0
max	max	NN	0
is	is	VBZ	0
the	the	DT	0
maximum	maximum	JJ	0
binding	binding	NN	0
at	at	IN	0
equilibrium	equilibrium	JJ	0
L	L	NNP	0
is	is	VBZ	0
the	the	DT	0
free	free	JJ	0
ligand	ligand	JJ	0
concentration	concentration	NN	0
and	and	CC	0
n	n	NN	0
is	is	VBZ	0
the	the	DT	0
Hill	Hill	NNP	0
coefficient	coefficient	NN	0
.	.	.	0
K	K	NNP	0
i	i	FW	0
determinations	determinations	FW	0
,	,	,	0
100	100	CD	0
μl	μl	NN	0
of	of	IN	0
homogenate	homogenate	NN	0
was	was	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
2	2	CD	0
hours	hours	NNS	0
with	with	IN	0
varying	varying	VBG	0
concentrations	concentrations	NNS	0
of	of	IN	0
inhibitor	inhibitor	NN	0
and	and	CC	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NNS	0
(	(	-LRB-	0
NEN	NEN	NNP	0
,	,	,	0
MA	MA	NNP	0
)	)	-RRB-	0
.	.	.	0
Binding	Binding	NNP	0
was	was	VBD	0
terminated	terminated	VBN	0
by	by	IN	0
rapid	rapid	JJ	0
filtration	filtration	NN	0
onto	onto	IN	0
a	a	DT	0
GF	GF	NNP	0
/	/	NNP	0
B	B	NNP	0
filters	filters	NNS	0
.	.	.	0
The	The	DT	0
IC	IC	NNP	0
50	50	CD	0
values	values	NNS	0
were	were	VBD	0
calculated	calculated	VBN	0
by	by	IN	0
fitting	fitting	VBG	0
the	the	DT	0
data	data	NNS	0
to	to	TO	0
the	the	DT	0
following	following	JJ	0
equation	equation	NN	0
using	using	VBG	0
Graphpad	Graphpad	NNP	0
PRISM	PRISM	NNP	0
(	(	-LRB-	0
San	San	NNP	0
Diego	Diego	NNP	0
CA	CA	NNP	0
)	)	-RRB-	0
:	:	:	0
θ	θ	CD	0
=	=	SYM	0
1	1	CD	0
/	/	CD	0
(	(	-LRB-	0
1+	1+	NNP	0
(	(	-LRB-	0
L	L	NNP	0
/	/	NNP	0
IC	IC	NNP	0
50	50	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
,	,	,	0
where	where	WRB	0
θ	θ	NN	0
is	is	VBZ	0
the	the	DT	0
fractional	fractional	JJ	0
amount	amount	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
bound	bound	VBN	0
in	in	IN	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
inhibitor	inhibitor	NN	0
at	at	IN	0
concentration	concentration	NN	0
L	L	NNP	0
as	as	RB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
bound	bound	VBN	0
in	in	IN	0
the	the	DT	0
absence	absence	NN	0
of	of	IN	0
inhibitor	inhibitor	NN	0
.	.	.	0
IC	IC	NNP	0
50	50	CD	0
is	is	VBZ	0
the	the	DT	0
concentration	concentration	NN	0
at	at	IN	0
which	which	WDT	0
θ	θ	VBD	0
=	=	CD	0
0.5	0.5	CD	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
is	is	VBZ	0
calculated	calculated	VBN	0
from	from	IN	0
the	the	DT	0
IC	IC	NNP	0
50	50	CD	0
value	value	NN	0
using	using	VBG	0
the	the	DT	0
Cheng-Prusoff	Cheng-Prusoff	JJ	0
equation	equation	NN	0
.	.	.	0
Electrophysiological	Electrophysiological	NNP	0
Recordings	Recordings	NNP	0
Transfected	Transfected	NNP	0
cells	cells	NNS	0
were	were	VBD	0
transferred	transferred	VBN	0
to	to	TO	0
a	a	DT	0
recording	recording	NN	0
chamber	chamber	NN	0
containing	containing	VBG	0
extracellular	extracellular	JJ	0
solution	solution	NN	0
(	(	-LRB-	0
140	140	CD	0
mM	mM	JJ	0
NaCl	NaCl	NN	0
,	,	,	0
1.7	1.7	CD	0
mM	mM	JJ	0
MgCl	MgCl	JJ	0
2	2	CD	0
,	,	,	0
5	5	CD	0
mM	mM	JJ	0
KCl	KCl	NN	0
,	,	,	0
1.8	1.8	CD	0
mM	mM	JJ	0
CaCl	CaCl	JJ	0
2	2	CD	0
,	,	,	0
25	25	CD	0
mM	mM	JJ	0
HEPES	HEPES	NNP	0
pH	pH	NNP	0
7.4	7.4	CD	0
)	)	-RRB-	0
.	.	.	0
Patch	Patch	JJ	0
electrodes	electrodes	NNS	0
of	of	IN	0
resistance	resistance	NN	0
2.5-3.0	2.5-3.0	NNP	0
MΩ	MΩ	NNP	0
were	were	VBD	0
filled	filled	VBN	0
with	with	IN	0
filtered	filtered	JJ	0
intracellular	intracellular	JJ	0
solution	solution	NN	0
containing	containing	VBG	0
145	145	CD	0
mM	mM	JJ	0
KCl	KCl	NN	0
,	,	,	0
2	2	CD	0
mM	mM	JJ	0
MgCl	MgCl	JJ	0
2	2	CD	0
,	,	,	0
1	1	CD	0
mM	mM	JJ	0
EGTA	EGTA	NNP	0
,	,	,	0
25	25	CD	0
mM	mM	JJ	0
HEPES	HEPES	NNP	0
(	(	-LRB-	0
pH	pH	NNP	0
7.4	7.4	CD	0
)	)	-RRB-	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
clamped	clamped	VBN	0
in	in	IN	0
whole	whole	JJ	0
cell	cell	NN	0
configuration	configuration	NN	0
at	at	IN	0
a	a	DT	0
holding	holding	NN	B-NP
potential	potential	NN	I-NP
of	of	IN	0
-60	-60	NNP	0
mV	mV	NNP	0
.	.	.	0
A	A	DT	0
continuous	continuous	JJ	B-NP
extracellular	extracellular	JJ	I-NP
solution	solution	NN	I-NP
flow	flow	NN	I-NP
(	(	-LRB-	0
0.8	0.8	FW	0
ml	ml	NN	B-NP
/	/	NN	I-NP
min	min	NNP	I-NP
)	)	-RRB-	0
was	was	VBD	0
maintained	maintained	VBN	0
throughout	throughout	IN	0
the	the	DT	0
recording	recording	NN	B-NP
procedure.	procedure.	NNP	I-NP
5-HT	5-HT	NNP	0
was	was	VBD	0
dissolved	dissolved	VBN	0
in	in	IN	0
extracellular	extracellular	JJ	B-NP
solution	solution	NN	I-NP
and	and	CC	0
delivered	delivered	VBN	0
to	to	TO	0
cells	cells	NNS	0
using	using	VBG	0
a	a	DT	0
rapid	rapid	JJ	B-NP
perfusion	perfusion	JJ	I-NP
system	system	NN	I-NP
(	(	-LRB-	0
Warner	Warner	NNP	0
Instruments	Instruments	NNP	0
,	,	,	0
Hamden	Hamden	NNP	0
,	,	,	0
CT	CT	NNP	B-NP
)	)	-RRB-	0
at	at	IN	0
a	a	DT	0
rate	rate	NN	0
matching	matching	VBG	0
the	the	DT	0
extracellular	extracellular	JJ	B-NP
solution	solution	NN	I-NP
flow	flow	NN	I-NP
rate	rate	NN	I-NP
.	.	.	0
The	The	DT	0
drug	drug	NN	0
perfusions	perfusions	VBZ	0
lasted	lasted	VBN	0
for	for	IN	0
a	a	DT	0
period	period	NN	0
varying	varying	VBG	0
from	from	IN	0
4	4	CD	0
to	to	TO	0
8	8	CD	0
seconds	seconds	NNS	0
.	.	.	0
Currents	Currents	JJ	0
elicited	elicited	NN	0
by	by	IN	0
agonist	agonist	JJ	B-NP
application	application	NN	I-NP
were	were	VBD	0
measured	measured	VBN	0
using	using	VBG	0
an	an	DT	0
Axopatch	Axopatch	NNP	B-NP
200	200	CD	0
B	B	NN	B-NP
amplifier	amplifier	NN	I-NP
(	(	-LRB-	0
Foster	Foster	NNP	0
City	City	NNP	0
,	,	,	0
CA	CA	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
data	data	NNS	0
were	were	VBD	0
plotted	plotted	JJ	0
and	and	CC	0
analyzed	analyzed	VBD	0
by	by	IN	0
non-linear	non-linear	JJ	B-NP
curve	curve	NN	I-NP
fit	fit	NN	I-NP
(	(	-LRB-	0
Graphpad	Graphpad	NNP	B-NP
PRISM	PRISM	NNP	I-NP
,	,	,	0
San	San	NNP	B-NP
Diego	Diego	NNP	I-NP
CA	CA	NNP	I-NP
)	)	-RRB-	0
according	according	VBG	0
to	to	TO	0
the	the	DT	0
following	following	JJ	0
equation	equation	NN	0
:	:	:	0
I	I	PRP	0
=	=	SYM	0
1	1	CD	0
/	/	CD	0
(	(	-LRB-	0
1	1	CD	0
+	+	CD	0
(	(	-LRB-	0
EC	EC	NNP	0
50	50	CD	0
/	/	CD	0
[	[	-LRB-	0
C	C	$	0
]	]	CD	0
)	)	-RRB-	0
n	n	NN	0
)	)	-RRB-	0
,	,	,	0
where	where	WRB	0
is	is	VBZ	0
the	the	DT	0
normalized	normalized	JJ	0
current	current	JJ	0
at	at	IN	0
5-HT	5-HT	CD	0
concentration	concentration	NN	0
[	[	-LRB-	0
C	C	NNP	0
]	]	-RRB-	0
,	,	,	0
EC	EC	NNP	B-NP
50	50	CD	0
is	is	VBZ	0
the	the	DT	0
concentration	concentration	NN	B-NP
of	of	IN	0
5-HT	5-HT	NNP	0
needed	needed	VBD	0
to	to	TO	0
obtain	obtain	VB	0
half	half	DT	0
maximal	maximal	JJ	B-NP
activation	activation	NN	I-NP
and	and	CC	0
n	n	NN	0
is	is	VBZ	0
the	the	DT	0
apparent	apparent	JJ	0
Hill	Hill	NNP	0
coefficient	coefficient	NN	0
.	.	.	0
